VU Research Portal

Targeted chemoprevention of head and neck cancer

de Boer, D.V.

2021

document version

Publisher's PDF, also known as Version of record

Link to publication in VU Research Portal

citation for published version (APA)

de Boer, D. V. (2021). Targeted chemoprevention of head and neck cancer.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain

• You may freely distribute the URL identifying the publication in the public portal ? Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Chapter 4

Chemopreventive targeted treatment of head

and neck precancer by Wee1 inhibition

'9LFN\GH%RHU $QQH0YDQ+DUWHQ 6DQQH50DUWHQVGH.HPS 0DULMNH%XLM]H6RQMD+*DQ]HYOHV.HLWK'+XQWHU&5HQp/HHPDQV 9LFWRU:YDQ%HXVHFKHP5RE0):ROWKXLV5HQpH;GH0HQH]HV 5XXG+%UDNHQKRͿ '9LFN\GH%RHUDQG$QQH0YDQ+DUWHQFRQWULEXWHGHTXDOO\WRWKLVZRUN 3XEOLVKHGLQ6FLHQWLÀF5HSRUWV2330.

 

4

INTRODUCTION +HDGDQGQHFNVTXDPRXVFHOOFDUFLQRPDV+16&&VDULVHLQWKHPXFRVDOOLQLQJRIWKH XSSHUDHURGLJHVWLYHWUDFWDQGDFFRXQWIRUDURXQGRIWKHWRWDOFDQFHULQFLGHQFH_. 7KHPDLQULVNIDFWRUVIRUKHDGDQGQHFNFDQFHUDUHVPRNLQJDQGH[FHVVLYHDOFRKRO FRQVXPSWLRQLQIHFWLRQZLWKDKLJKULVNW\SHRIWKHKXPDQSDSLOORPDYLUXV+39RU JHQHWLFSUHGLVSRVLWLRQVXFKDV)DQFRQLDQHPLD)$2_{)$LVFKDUDFWHUL]HGE\FRQJHQLWDO}

DEQRUPDOLWLHV SURJUHVVLQJ DQHPLD DQG FDQFHU SUHGLVSRVLWLRQ SDUWLFXODUO\ RI RUDO FDQFHUV7KHVHWXPRUVDUHGL΀FXOWWRPDQDJHDV)$SDWLHQWVDUHVHQVLWLYHWRFURVV OLQNLQJDJHQWVVXFKDVFLVSODWLQKDPSHULQJFOLQLFDOPDQDJHPHQWRIWXPRUVDQGIRU WKHVHSDWLHQWVVXUYHLOODQFHDQGSUHYHQWLRQLVNH\

7XPRUVLQWKHKHDGDQGQHFNUHJLRQGHYHORSLQSUHPDOLJQDQWPXFRVDOFKDQJHVODUJH HSLWKHOLDO DUHDV FKDUDFWHUL]HG E\ FDQFHUDVVRFLDWHG JHQHWLF FKDQJHV DOVR UHIHUUHG WR DV ¶ÀHOGV· 7KHVH SUHFDQFHURXV ÀHOGV FDQ EH FHQWLPHWHUV LQ VL]H DQG DUH RIWHQ PDFURVFRSLFDOO\LQYLVLEOH$PLQRULW\PDQLIHVWVDVYLVLEOHPXFRVDOOHVLRQVNQRZQDV OHXNRSODNLDRUHU\WKURSODNLDZKLFKRFFXUZLWKDSUHYDOHQFHRIDURXQG²IRU OHXNRSODNLD_{DQG²IRUHU\WKURSODNLD}_{(YHU\\HDU²RIWKHOHXNRSODNLD}

OHVLRQVSURJUHVVLQWRFDQFHUDQGHU\WKURSODNLDOHVLRQVLQHYLWDEO\SURJUHVV

'HVSLWH WKH RFFXUUHQFH DQG SUHYDOHQFH RI WKHVH YLVLEOH OHVLRQV WKH ODUJH PDMRULW\ RI KHDG DQG QHFN FDQFHUV GHYHORS de novo ,Q UHVHFWHG WXPRU VSHFLPHQ KRZHYHU SUHFHGLQJ SUHPDOLJQDQW FKDQJHV FDQ EH RIWHQ LGHQWLÀHG LQ WKH VXUJLFDO PDUJLQV E\ HLWKHU PLFURVFRSLF GHWHFWLRQ RI G\VSODVLD RU E\ JHQHWLF DQDO\VLV5_{ :KHQ WKHVH}

ÀHOGV DUH LQFRPSOHWHO\ UHPRYHG DIWHU WXPRU H[FLVLRQ WKH\ RIWHQ OHDG WR D ORFDO UHODSVH_{ 0RUHRYHU LQGHSHQGHQW ÀHOGV PD\ H[LVW WKDW GLG QRW XQGHUJR PDOLJQDQW}

WUDQVIRUPDWLRQ\HWDQGPD\FDXVHVHFRQGSULPDU\WXPRUV_.

7KHVH SUHPDOLJQDQW ÀHOGV DUH GL΀FXOW WR PDQDJH FOLQLFDOO\ 6PDOO YLVLEOH OHVLRQV FDQ EH H[FLVHG RU WUHDWHG XVLQJ ODVHU 8QIRUWXQDWHO\ H΀FDF\ LV OLPLWHG DV OHVLRQV IUHTXHQWO\ UHFXU DQG VXEVHTXHQWO\ XQGHUJR PDOLJQDQW WUDQVIRUPDWLRQ RU WXPRUV PD\GHYHORSHOVHZKHUH/DUJHUOHVLRQVDQGÀHOGVWKDWDUHQRWYLVLEOHFDQQRWEHWUHDWHG \HW²_{:KHQWXPRUVRFFXUWUHDWPHQWLVREYLRXVO\IRFXVHGRQWKHLQGH[WXPRUZKLFK}

PD\FRPSULVHRIVXUJLFDOUHVHFWLRQZLWKRUZLWKRXWSRVWRSHUDWLYHSODWLQXPEDVHG FKHPR UDGLRWKHUDS\ RU XSIURQW FKHPRUDGLRWKHUDS\_{. Despite these invasive}

WUHDWPHQWSURWRFROVORFDOUHODSVHVIUHTXHQWO\RFFXUHYHQZKHQWKHVXUJLFDOPDUJLQV DUH KLVWRORJLFDOO\ WXPRUIUHH DQG RIWHQ GHYHORS IURP ÀHOGV WKDW VWD\HG EHKLQG XQQRWLFHG2_{,PSURYHPHQWRIWKHUDS\SURWRFROVLVWKHUHIRUHQHFHVVDU\WRWUHDWQRWRQO\}

WKHWXPRUVPRUHHͿHFWLYHO\EXWDOVRWKHVHSUHPDOLJQDQWÀHOGV7DUJHWHGWUHDWPHQW DSSURDFKHVVHHPDQDWWUDFWLYHRSWLRQKRZHYHUWDUJHWDEOHPXWDWLRQVLQRQFRJHQHV UDUHO\RFFXULQKHDGDQGQHFNSUHFDQFHUKDPSHULQJWKHLGHQWLÀFDWLRQRIVXLWDEOH GUXJ WDUJHWV_{ $ VHFRQG SUREOHP LQ GHVLJQLQJ QRYHO WDUJHWHG FKHPRSUHYHQWLYH} ABSTRACT

+39QHJDWLYH KHDG DQG QHFN VTXDPRXV FHOO FDUFLQRPDV +16&&V GHYHORS LQ SUHFDQFHURXVFKDQJHVLQWKHPXFRVDOOLQLQJRIWKHXSSHUDHURGLJHVWLYHWUDFW7KHVH SUHFDQFHURXV FHOOV FRQWDLQ FDQFHUDVVRFLDWHG JHQRPLF FKDQJHV DQG FDXVH SULPDU\ WXPRUV DQG ORFDO UHODSVHV 7KHUDSHXWLF VWUDWHJLHV WR HUDGLFDWH WKHVH SUHFDQFHURXV FHOOVDUHYHU\OLPLWHG8VLQJIXQFWLRQDOJHQRPLFVFUHHQVZHLGHQWLÀHGWKHWKHUDSHXWLF YXOQHUDELOLWLHVRISUHPDOLJQDQWPXFRVDOFHOOVZKLFKDUHVKDUHGZLWKIXOO\PDOLJQDQW +16&&FHOOV:HVFUHHQHGSUHYLRXVO\LGHQWLÀHGWXPRUOHWKDOVL51$VRQDSDQHORI FDQFHUDQGSUHFDQFHURXVFHOOOLQHVDVZHOODVSULPDU\ÀEUREODVWV,QWRWDOZHLGHQWLÀHG WXPRUHVVHQWLDOJHQHVLQFOXGLQJGUXJJDEOHFDQGLGDWHV2IWKHVHZHUH DOVRHVVHQWLDOLQSUHPDOLJQDQWFHOOV:HLQYHVWLJDWHGWKHYDULDEOHPROHFXODUEDVLVRI WKH YXOQHUDELOLWLHV LQ WXPRU DQG SUHPDOLJQDQW FHOO OLQHV DQG IRXQG LQGLFDWLRQV RI FROODWHUDOOHWKDOLW\:HHOLNHNLQDVH:((ZDVDPRQJVWWKHPRVWSURPLVLQJWDUJHWV IRUERWKWXPRUDQGSUHFDQFHURXVFHOOV$OOIRXUSUHFDQFHURXVFHOOOLQHVZHUHKLJKO\ VHQVLWLYHWR:HHLQKLELWLRQE\$GDYRVHUWLE$='ZKLOHSULPDU\NHUDWLQRF\WHV WROHUDWHG WKLV LQKLELWRU :HH LQKLELWLRQ FDXVHG LQGXFWLRQ RI '1$ GDPDJH GXULQJ 6SKDVHIROORZHGE\PLWRWLFIDLOXUHLQSUHFDQFHUFHOOV,QFRQFOXVLRQZHXQFRYHUHG :HHLQKLELWLRQDVDSURPLVLQJFKHPRSUHYHQWLYHVWUDWHJ\IRUSUHFDQFHURXVFHOOVZLWK FRPSDUDEOHUHVSRQVHVDVIXOO\WUDQVIRUPHG+16&&FHOOV

 

4

RIWKHSRVLWLYHHJVLUBB8ELTXLWLQ%LQUHGDQGQHJDWLYHFRQWUROVVL&21752/ LQEOXH)LJXUHD$VH[SHFWHGWKHPDMRULW\RIWKHSUHVHOHFWHGVL51$VLQEODFN KDGDOHWKDOHͿHFWLQPRVWFHOOOLQHV7RLGHQWLI\WKHVL51$60$57SRROVWKDWLQGXFHG DUHOHYDQWGHFUHDVHLQFHOOYLDELOLW\PHGLDQYDOXHVSHUFHOOOLQHZHUHFDOFXODWHGDQG WKHFXWRͿIRUVHOHFWLRQZDVVHWDWDYLDELOLW\VFRUHRIï8VLQJWKLVFXWRͿ!RI WKHQHJDWLYHFRQWUROVZHUHVFRUHGDVQHJDWLYHDQGDOOSRVLWLYHFRQWUROVZHUHVFRUHG as positive.

Table 1: Overview of cells screened with the tumor-lethal library.

Cell line Type Site Doubling time (h) Method of

trans-fection Transfection reagent Cells per well Volume reagent ZHOOۙO )LEUREODVWV

 3ULPDU\ ÀEUREODVWV 8YXOD  Reverse 51$L0D[  

)LEUREODVWV

 3ULPDU\ÀEUREODVWV 8YXOD  Reverse 51$L0D[  

)LEUREODVWV

98 3ULPDU\ÀEUREODVWV U  Reverse 51$L0D[  

986&&

reference +39QHJDWLYHWXPRU 7RQJXH  )RUZDUG DharmaFECT   

986&&2( +39QHJDWLYH

WXPRU )ORRURIPRXWK  Reverse DharmaFECT  

806&&% +39QHJDWLYH

WXPRU /DU\Q[ 22 )RUZDUG DharmaFECT   

806&&% +39QHJDWLYH

WXPRU +\SRSKDU\Q[  )RUZDUG DharmaFECT   

986&& )$GHULYHG

WXPRU )ORRURIPRXWK  Reverse 51$L0D[  

98

6&& )$GHULYHGWXPRU 0RXWKPXFRVD  Reverse 51$L0D[  

&&+)$+1

6&& )$GHULYHGWXPRU U  Reverse 51$L0D[  

98

6&& )$GHULYHGWXPRU 7RQJXH  Reverse 51$L0D[  

806&& +39

SRVLWLYHWXPRU /DWHUDOWRQJXH  )RUZDUG DharmaFECT   

986&& +39

SRVLWLYHWXPRU )ORRURIPRXWK 25 Reverse DharmaFECT  

876&& +39

SRVLWLYHWXPRU 2UDOFDYLW\  )RUZDUG DharmaFECT   

806&& +39

SRVLWLYHWXPRU )ORRURIPRXWK  Reverse DharmaFECT  

88QNQRZQ)$)DQFRQLDQHPLD+39+XPDQ3DSLOORPDYLUXV

VWUDWHJLHVLVWKHODFNRIin vivoPRGHOVIn vitroSUHPDOLJQDQWRUDOFHOOPRGHOVKDYH EHHQGHYHORSHGEXWWKHVHGRQRWIRUPGHWHFWDEOHSUHPDOLJQDQFLHVLQin vivo [HQRJUDIW PRGHOVFRPSOLFDWLQJSUHFOLQLFDOLQYHVWLJDWLRQV5_.

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{ :LWK WKH ORVV RI D ORFXV FRQWDLQLQJ D WXPRU VXSSUHVVRU}

JHQH QHLJKERULQJ JHQHV DUH RIWHQ DͿHFWHG DV ZHOO ZKLFK FDXVHV KRPR]\JRXV RU KHWHUR]\JRXVGHOHWLRQVRIWKHVHSDVVHQJHUJHQHV_{. Loss of some of these passenger}

JHQHV PD\ FDXVH VHQVLWLYLW\ WR LQKLELWLRQ E\ VL51$V RU GUXJV RU WKH FHOO EHFRPHV IXOO\GHSHQGHQWRQWKHSDUDORJXHRIWKHSDUWLDOO\ORVWJHQH7KHVHYXOQHUDELOLWLHVDUH QDPHGFROODWHUDOOHWKDOLW\DQGWKHVHJHQHVFDQEHH[SORUHGDVWKHUDSHXWLFWDUJHWV_.

7R LQYHVWLJDWH QHZ WKHUDSHXWLF DSSURDFKHV WR WDUJHW WKH LQYDVLYH FDQFHUV ZH SUHYLRXVO\SHUIRUPHGJHQRPHZLGH51$LQWHUIHUHQFH51$LVFUHHQV_{DQGDSDQHO}

RI RYHU  WXPRUOHWKDO VL51$V ZHUH LGHQWLÀHG ,Q WKH FXUUHQW VWXG\ ZH XVHG D FXVWRPOLEUDU\RIWKHVHOHWKDOVL51$VWRIXUWKHULQYHVWLJDWHWKHYXOQHUDELOLWLHVRIERWK FDQFHUDQGSUHPDOLJQDQWFHOOVFRPSDUHGWRQRUPDOSULPDU\FHOOV

RESULTS

,GHQWLÀFDWLRQRIHVVHQWLDOJHQHV

:H FRQVWUXFWHG D FXVWRP VL51$ 60$57SRRO OLEUDU\ )LJXUH 6D EDVHG RQ KLW VHOHFWLRQLQSUHYLRXVO\SHUIRUPHGDUUD\EDVHGJHQRPHZLGHVL51$VFUHHQVLQWZR WXPRUFHOOOLQHV7KHOLEUDU\FRQVLVWHGRIVL51$VWDUJHWLQJJHQHVWKDWZHUHIRXQG WREHHVVHQWLDOLQWKHVHLQLWLDOWZRWXPRUFHOOOLQHV_{5HVFUHHQLQJRIWKHFXVWRPOLEUDU\}

LQWKHRULJLQDOO\VFUHHQHG+16&&FHOOOLQHUHYHDOHGFRQÀUPDWLRQRIRIWKHKLWV_,

LQGLFDWLQJ WKH DFFXUDF\ RI WKH DSSURDFK DQG WKHVH GDWD ZHUH DOVR LQFOXGHG LQ WKLV VWXG\DVDUHIHUHQFH_{+HUHZHH[WHQGHGWKHFHOOOLQHSDQHOZLWKWKUHH+39QHJDWLYH} DQGIRXU+39SRVLWLYH+16&&FHOOOLQHVDQGLQDGGLWLRQZLWKIRXU+39QHJDWLYH +16&&FHOOOLQHVHVWDEOLVKHGIURPKHDGDQGQHFNWXPRUVLQ)DQFRQLDQHPLD)$ SDWLHQWV:HIXUWKHULQFOXGHGSULPDU\QRQWUDQVIRUPHGRUDOÀEUREODVWVRIWZRKHDOWK\ GRQRUVDQGRQH)$SDWLHQWWRLGHQWLI\WXPRUVSHFLÀFOHWKDOLW\7DEOHDQG)LJXUH 6E1RUPDOL]HG/RJWUDQVIRUPHGGDWDSRLQWVGHPRQVWUDWHGDQDFFXUDWHVHSDUDWLRQ

 

4

WKH+39SRVLWLYH+16&&OLQHVDQGLQJUHHQWKUHHQRQWUDQVIRUPHGÀEUREODVWFXOWXUHV7KHFOXVWHU DQDO\VLVUHYHDOHGQRGLͿHUHQFHVEHWZHHQWKHFDQFHUVXEJURXSV0RVWREYLRXVDUHWKHORZQXPEHUV RIKLWVLQWKHQRUPDOSULPDU\FHOOVc.1XPEHURIOHWKDOVL51$60$57SRROVZLWKDYLDELOLW\VFRUH RI ” ï SHU FHOO OLQH ,Q DOO WKUHH QRQWUDQVIRUPHG RUDO ÀEUREODVWV OHVV WKDQ  HVVHQWLDO JHQHV ZHUHIRXQGd–h.$OOVFUHHQHGFHOOOLQHVZHUHGLYLGHGRQWKHEDVLVRIJHQRPLFORVVDQDO\VLVLQWZR JURXSVHLWKHUWKHFHOOOLQHZDV&1QHXWUDORUKDGDKHWHUR]\JRXV&1DOWHUDWLRQRIWKHELQVZKHUH

RPSA dRPL14 eRPL17 fPSMD6 gRURPS20 hDUHORFDWHG7KHJURXSZLWKRXWDEHUUDWL

RQVGLVSOD\HGVLJQLÀFDQWOHVVUHGXFWLRQLQFHOOYLDELOLW\XSRQNQRFNGRZQRIRPSA WZRVLGHGt test,

P  RPL14 WZRVLGHGt test, P RPL17 WZRVLGHGt test, P  DQGPSMD6WZR

sided t test, P  )RURPS20QRVLJQLÀFDQWFRUUHODWLRQZDVIRXQGEHWZHHQ&1VWDWXVDOOHOLF JDLQDQGVL51$YLDELOLW\

Cluster analysis of median viability scores

8QVXSHUYLVHGFOXVWHUDQDO\VLVRIWKHQRUPDOL]HGDQGWUDQVIRUPHGPHGLDQFHOOYLDELOLW\ YDOXHVGLGQRWUHYHDOFOHDUGLͿHUHQFHVEHWZHHQWKH)$SDWLHQWGHULYHG+39SRVLWLYH DQG+39QHJDWLYHWXPRUFHOOOLQHV)LJXUHEDQG6F,QVWHDGWZRPDLQFOXVWHUV ZHUHIRXQGZKLFKVHHPHGWRFRUUHVSRQGPDLQO\WRWKHQXPEHURIKLWVLGHQWLÀHG DQG!)LJXUHF:LWKLQWKHFOXVWHUZLWKHVVHQWLDOJHQHVWKHSULPDU\ ÀEUREODVWVIRUPHGDVHSDUDWHJURXS7KHVHSDUDWLRQLQWRWZRFOXVWHUVQHLWKHUUHODWHG WR GLͿHUHQFHV LQ WUDQVIHFWLRQ UHDJHQW QRU WR UHYHUVH RU IRUZDUG WUDQVIHFWLRQ QRU WR FHOO GRXEOLQJ WLPH_{ 1H[W ZH DVVHVVHG WKH QXPEHU RI LGHQWLÀHG OHWKDO VL51$}

60$57SRROVSHUFHOOOLQH)LJXUHF7KLVQXPEHUUDQJHGIURPÀEUREODVWFXOWXUH WR806&&%ZLWKDPHGLDQRI0RVWSURPLQHQWZHUHWKHORZQXPEHUV RIOHWKDOVL51$VLQWKHSULPDU\ÀEUREODVWVOHVVWKDQVL51$VZHUHOHWKDOIRUDOO WKUHH GRQRUV 7KH GLͿHUHQFH LQ OHWKDO KLWV EHWZHHQ SULPDU\ ÀEUREODVWV DQG WXPRU FHOOVUHYHDOVDQH[SORLWDEOHZLQGRZIRUVHOHFWLYHWXPRUFHOOWDUJHWLQJWKHUDSLHV

Collateral lethality analysis

7KH FRQFHSW RI FROODWHUDO OHWKDOLW\ DVVRFLDWHV JHQRPLF DEHUUDWLRQV LQ WXPRU FHOOV WR VSHFLÀFYXOQHUDELOLWLHVRIJHQHLQWHUIHUHQFHLQWKHVHFHOOV:HK\SRWKHVL]HGWKDWVRPH LGHQWLÀHGOHWKDOKLWVZLWKLQRXUUHVFUHHQFRXOGEHH[SODLQHGE\DKHWHUR]\JRXVORVVRU DPSOLÀFDWLRQRIWKHUHODWHGFKURPRVRPDOORFXV7KHUHIRUHZHDGDSWHGDQGDSSOLHG DQLQWHJUDWHGDQDO\VLVDVSUHYLRXVO\GHVFULEHGE\0HQH]HVet al._{RIWKHFHOOOLQH'1$}

FRS\ QXPEHU &1 GDWD SHU FKURPRVRPH DUP_{ DQG WKH VL51$ OHWKDOLW\ GDWD SHU}

FHOOOLQH$EHUUDWLRQVRIFKURPRVRPHDUPVSSSTTDQGTGHPRQVWUDWHG VLJQLÀFDQWDVVRFLDWLRQVZLWKVSHFLÀFVL51$YXOQHUDELOLWLHVRIJHQHVORFDWHGDWWKHVH ORFL7DEOH:HLGHQWLÀHGSRVLWLYHSDUWLDOFRUUHODWLRQVEHWZHHQVL51$VDQGORVVHV DWFKURPRVRPHDUPVSSDQGT=VFRUH!DQGQHJDWLYHSDUWLDOFRUUHODWLRQV EHWZHHQ VL51$V DQG JDLQV DW FKURPRVRPH DUPV S T DQG T =VFRUH  ï $VVRFLDWLRQVZLWKJDLQVDQGDPSOLÀFDWLRQVPD\SRLQWWRFROODWHUDOJHQHDGGLFWLRQV ZKLOHDVVRFLDWLRQVZLWKORVVHVLQGLFDWHVDPRUHFODVVLFDOFROODWHUDOOHWKDOLW\/RVVRI RQHFRS\RIDWXPRUVXSSUHVVRUJHQHE\DSDUWLDOFKURPRVRPDOORVVOLNHO\UHGXFHV

a

b

c

d

e

f

g

h

c

d

e

f

g

h

)LJXUH6FUHHQLQJRIWXPRUOHWKDOVL51$VRQDSDQHORIFDQFHUSUHPDOLJQDQWDQGQRUPDO primary cell cultures and the exploitation of collateral lethality. a. 'LVWULEXWLRQ RI DOO VL51$V LV VKRZQ 7KH [D[LV UHSUHVHQWV WKH YLDELOLW\ VFRUH QRUPDOL]HG ORJ WUDQVIRUPHG YDOXHV 7KH \D[LV UHSUHVHQWVWKHGHQVLW\VFRUHRIWKHVL51$V,QUHGDOOSRVLWLYHFRQWUROVVLUBBDUHVKRZQDQGLQ EOXHDOOQHJDWLYHFRQWUROVVL&21752/DUHGHSLFWHG$QDFFXUDWHVHSDUDWLRQEHWZHHQWKHFRQWUROV ZDVREWDLQHG7KHEODFNOLQHUHSUHVHQWVDOOVL51$VZKLFKZHUHFRQVLGHUHGOHWKDODWWKHYLDELOLW\ VFRUHFXWRͿ”ïb.&OXVWHUDQDO\VLVRIWKHWZHOYHUHVFUHHQHG+16&&FHOOOLQHV7KH+39QHJDWLYH +16&&OLQHVDUHSUHVHQWHGLQUHGLQEOXHWKH+16&&OLQHVIURP)DQFRQLDQHPLDSDWLHQWVLQ\HOORZ

 

4

.(**SDWKZD\DQDO\VLVXVLQJ'$9,'UHYHDOHGWKDWWKHWXPRUVSHFLÀFVL51$V FDQEHFODVVLÀHGLQVHYHQIXQFWLRQDOVXEJURXSVZKHUHDVWKHFRUHHVVHQWLDOJHQHV ZHUHPDLQO\ULERVRPDO)LJXUH6DE_{)RUIXUWKHUVHOHFWLRQRIWKHKLWVZHPLQHG} D¶GUXJWRJHQHLQWHUDFWLRQ·GDWDEDVHDQGWKLVUHYHDOHGGUXJJDEOHJHQHV7DEOH6_. 7RIXUWKHUVHOHFWFDQGLGDWHVL51$60$57SRROVWKDWWDUJHWSUHPDOLJQDQWFHOOVDVZHOO ZHLQWHUURJDWHGDQGUHDQDO\]HGWKHGDWDRIWKHSUHYLRXVO\VFUHHQHGSUHFDQFHURXVFHOO OLQH98SUH6&&0ZLWKWKHVDPHVL51$V_{7KLVUHYHDOHGWKDWJHQHVRXWRI} WKHGUXJJDEOHHVVHQWLDOJHQHVLQFDQFHUFHOOVDUHDOVRHVVHQWLDOLQSUHFDQFHURXVFHOOV 7DEOH67KHWRSÀYHOHWKDOVL51$VLQ98SUH6&&0ZHUHGLUHFWHGDJDLQVWKIF11, RRM1, NHP2L1, :((and SF3B1DQGDOOVKRZHGHͿHFWLQDWOHDVWRXWRIWXPRU FHOOOLQHV7DEOH6KIF11 HQFRGHVIRUDPLWRWLFVSLQGOHSURWHLQDQGZDVSUHYLRXVO\ LGHQWLÀHG WR EH WXPRUOHWKDO LQ +16&&_{. RRM1 LV LQYROYHG LQ GHR[\QXFOHRWLGH}

V\QWKHVLVDQGFHOOF\FOHSURJUHVVLRQ,WLVDOVRDFHOOXODUWDUJHWIRUDFKHPRWKHUDSHXWLF DJHQW JHPFLWDELQH ,QWHUHVWLQJO\ NPH2L1 and SF3B1 DUH VSOLFH IDFWRUV DQG ERWK FDQFHUDQGSUHFDQFHURXVFHOOVGLVSOD\HGDQLQFUHDVHGGHSHQGHQF\RQVSOLFLQJ_.

7KHPRVWSURPLVLQJKLWIRUFOLQLFDOLPSOLFDWLRQWRWDUJHWSUHPDOLJQDQWVTXDPRXVFHOOV VHHPHG:HHOLNHNLQDVH:((DNH\FRPSRQHQWLQFHOOF\FOHFRQWUROWKDWUHJXODWHV WKH DFWLYLWLHV RI F\FOLQ ERXQG &'. DQG &'. 7KH :HH LQKLELWRU $GDYRVHUWLE IRUPHUO\ NQRZQ DV 0. DQG $=' LV FXUUHQWO\ XQGHU LQYHVWLJDWLRQ LQ FOLQLFDO WULDOV WR WUHDW VROLG WXPRUV DQG VHHPV SURPLVLQJ IRU RYDULDQ DQG KHDG and neck cancer_{ :H WKHUHIRUH LQYHVWLJDWHG WKH SRWHQWLDO RI :HH LQKLELWLRQ DV}

FKHPRSUHYHQWLYHVWUDWHJ\IRUPXFRVDOSUHFDQFHULQFOXGHG+16&&WXPRUFHOOOLQHV DQGDOVRUHODWHGWKHÀQGLQJVWRRYDULDQFDQFHUFHOOVDVUHIHUHQFH

WEE1

as druggable target in (pre)malignant cells

$OOWXPRUFHOOOLQHVVKRZHGDGHFUHDVHGFHOOYLDELOLW\ZLWKDYDOXHӕXSRQ

:((

NQRFNGRZQH[FHSW986&&7DEOH63ULPDU\RUDOÀEUREODVWVDOVRUHVSRQGHG VOLJKWO\WR

:((

NQRFNGRZQEXWGLGQRWUHDFKWKHFXWRͿ

:HQH[WGHFRQYROXWHGWKHVL

:((

60$57SRROLQVHYHUDOFHOOOLQHVWRFRQÀUPWKH UHVFUHHQLQJ UHVXOWV )LJXUH DH 7ZR RXW RI IRXU LQGLYLGXDO VL51$V KDG VLPLODU HͿHFWVRQWKHYLDELOLW\RI98SUH6&&0DQG+16&&FHOOOLQHVDVWKH60$57SRRO ,QFRQWUDVWWKH\GLGQRWDͿHFWWKHYLDELOLW\RISULPDU\RUDOÀEUREODVWVLQGLFDWLQJD WKHUDSHXWLFZLQGRZLQOLQHZLWKWKHUHVXOWVIURPWKHVL51$UHVFUHHQ$QHDUFRPSOHWH :HHSURWHLQNQRFNGRZQZDVREVHUYHGIRUWKHSRROHGVL51$VDQGVL

:((

#2 and KSRVWWUDQVIHFWLRQZKHUHDVNQRFNGRZQZLWKVL

:((

DQGUHVXOWHGLQD VOLJKWO\UHGXFHGSURWHLQOHYHO)LJXUHIDQREVHUYDWLRQFRQFRUGDQWZLWKWKHVL51$ WUDQVIHFWLRQHͿHFWVRQFHOOYLDELOLW\)LJXUHF H[SUHVVLRQRIQHLJKERULQJJHQHVDQGPD\LQFUHDVHYXOQHUDELOLW\WRVL51$VWDUJHWLQJ WKHVH )RXU FDQGLGDWH JHQHV ZLWK D SRVLWLYH FRUUHODWLRQ RPSA, RPL14, RPL17 and

PSMD6DQGRQHZLWKDQHJDWLYHFRUUHODWLRQRPS20ZHUHIXUWKHULQYHVWLJDWHGE\

NQRFNGRZQRIH[SUHVVLRQRIWKHVHJHQHVZLWKWKHUHOHYDQWVL51$60$57SRRO$OO WKHVH JHQHV H[FHSW SURWHDVRPH VXEXQLW PSMD6 HQFRGH IRU ULERVRPDO SURWHLQV &1GDWDRIWKHVHVSHFLÀFJHQHVUHYHDOHGWKDWWKHYLDELOLW\DIWHUWUDQVIHFWLRQLQGHHG SRVLWLYHO\FRUUHODWHGWRORVVHVIRURPSA, RPL14, RPL17 and PSMD6ZLWKSYDOXHVRI DQGUHVSHFWLYHO\)LJXUHGK7KHVHGDWDLQGLFDWHWKDWFROODWHUDO OHWKDOLW\E\WDUJHWLQJQHLJKERULQJJHQHVFRXOGLQGHHGH[SODLQDQXPEHURIWXPRU VSHFLÀFKLWVDQGVHHPVWRIRUPDJHQXLQHEDVLVIRUKLWVHOHFWLRQ

Table 2: Collateral lethality.

Gene Location RPSA S RPS20 T RPL14 S RPL17 T PSMD6 S PSMA2 S 6(&* S HNRNPK T RPL30 T RPL8 T PRPF18 S SNRPD1 T

Hit selection in cancer and precancer cell lines

7KH NQRFNGRZQ HͿHFW RI PDQ\ JHQHV ZDV WXPRU FHOO OLQHVSHFLÀF LQGLFDWLQJ D ODUJHYDULDWLRQLQYXOQHUDELOLWLHVDQGOLPLWLQJDSSOLFDELOLW\RISRWHQWLDOLQKLELWRUVDV D SDQ+16&& WUHDWPHQW VWUDWHJ\ :H WKHUHIRUH PLQHG RXU UHVFUHHQ VL51$ GDWD IRU VKDUHGYXOQHUDELOLWLHVDFURVVPXOWLSOHWXPRUFHOOOLQHV7DEOH62XUFULWHULRQRID SDQ+16&&OHWKDOKLWZDVDUELWUDULO\FKRVHQDVDYLDELOLW\VFRUH”ïLQDWOHDVW RXWWXPRUFHOOOLQHUHSOLFDWHV$GGLWLRQDOO\JHQHVZHUHFODVVLÀHGDV¶FRUHÀWQHVV· genes_{ LQ ERWK WXPRU FHOOV DQG QRUPDO FHOOV ZKHQ NQRFNGRZQ ZDV DOVR OHWKDO LQ}

PRUHWKDQRXWÀEUREODVWUHSOLFDWHV,QWRWDORXWRIVL51$60$57SRROV PHWWKHFULWHULRQ¶SDQ+16&&OHWKDO·ZKHUHDVRIWKHVHVL51$60$57SRROVZHUH DOVROHWKDOLQVL[RUPRUHÀEUREODVWUHSOLFDWHV7KLVUHVXOWHGLQSDQ+16&&WDUJHW JHQHVDQGFRUHÀWQHVVJHQHV7DEOH6

 

4

LQGHSHQGHQW GRQRUV VKRZHG D UHPDUNDEOH ELSKDVLF UHVSRQVH ZKLFK PD\ VXJJHVW LQKLELWLRQRIDVHFRQGDU\WDUJHWRI$GDYRVHUWLEDͿHFWLQJÀEUREODVWVVSHFLÀFDOO\:H FRXOGQRWGHWHUPLQHWKH(&_YDOXHVRIWKHÀEUREODVWVGXHWRWKLVELSKDVLFUHVSRQVH 7KH WHVWHG SULPDU\ NHUDWLQRF\WHV GLG QRW VKRZ D ELSKDVLF UHVSRQVH DQG WKH (&

YDOXHVZHUHWRWLPHVKLJKHUWKDQWKH(&YDOXHRIFHOOOLQH806&&KLJKHVW EC_RU806&&$ORZHVW(&_UHVSHFWLYHO\)LJXUHJ7KHWKHUDSHXWLFZLQGRZ EHWZHHQWKHSULPDU\NHUDWLQRF\WHVRQWKHRQHKDQGDQGWKHVTXDPRXVFDQFHUDQG SUHFDQFHURXVFHOOVRQWKHRWKHUDVZHOODVWKHFRPSDUDEOHUHVSRQVHVLQFRPSDULVRQ WRRYDULDQWXPRUFHOOOLQHVDUHSURPLVLQJIRUFOLQLFDODSSOLFDWLRQVRI$GDYRVHUWLELQ +16&&DQGRUDOSUHFDQFHU

&RPELQDWLRQ RI :HH LQKLELWLRQ ZLWK ոLUUDGLDWLRQ RU 3$53 LQKLELWLRQ KDYH EHHQ XQGHULQYHVWLJDWLRQIRURWKHUFDQFHUW\SHV²_{'HVSLWHUHSRUWVRIDGGLWLYHRUV\QHUJLVWLF} HͿHFWVLQRWKHUWXPRUFHOOPRGHOVFRPELQLQJ:HHLQKLELWLRQZLWKLUUDGLDWLRQGLG QRWUHYHDODQDGGLWLRQDOWKHUDSHXWLFHͿHFWIRU+16&&FHOOOLQHV$OVRWKHFRPELQDWLRQ RI$GDYRVHUWLEZLWKWKHKLJKO\VSHFLÀF3$53FDWDO\WLFLQKLELWRUDQGSRWHQWWUDSSHURI 3$537DOD]RSDULEGLGQRWHQKDQFHWKHUDSHXWLFH΀FDF\LQ+16&&GHULYHGFHOOOLQHV )LJXUH6DE %HVLGHV:HHDQG&'&&KNSOD\VDNH\UROHLQFHOOF\FOHFRQWURODQGUHJXODWLRQ RI&'.DFWLYLW\DQGZHZRQGHUHGZKHWKHUUHVSRQVHVWR&KNLQKLELWRUVFRUUHODWH WRWKRVHRI:HHLQKLELWRUV$OWKRXJKWKHFHOOOLQHSDQHOLVVPDOOQRFRUUHODWLRQZDV IRXQG EHWZHHQ VHQVLWLYLWLHV WR &KN LQKLELWLRQ ZLWK 5DEXVHUWLE /<_and

:HHLQKLELWLRQ)LJXUH6Fn 3HDUVRQ·VFRUUHODWLRQr ïP LPSO\LQJ GLVWLQFW UHJXODWRU\ PHFKDQLVPV )XUWKHUPRUH QR FRUUHODWLRQ ZDV IRXQG EHWZHHQ FHOOOLQHVHQVLWLYLW\WRFLVSODWLQWUHDWPHQW_{DQG:HHLQKLELWLRQ)LJXUH6Gn }

3HDUVRQ·VFRUUHODWLRQr P ZKLFKVXJJHVWVWKDWSDWLHQWVZKRGRQRW UHVSRQGWRFODVVLFDOFKHPRUDGLDWLRQZLWKFLVSODWLQPLJKWEHZHOOWUHDWDEOHE\:HH LQKLELWRUV)LJXUHJ

Wee1 inhibition and cell cycle progression

,Q +16&& FHOO F\FOH FRQWURO LV IUHTXHQWO\ DEURJDWHG DW *6 E\ VRPDWLF FKDQJHV LQ

CDKN2AF\FOLQ'DQGTP538_{3UHPDWXUH6SKDVHHQWU\FDXVHVUHSOLFDWLRQVWUHVVDQG}

GHPDQGVPRUHSUHFLVH6SKDVHFRQWUROE\&KN_{DQGFRQWURODW*07KHFRPSOH[}

RI&'.&\FOLQ%LVWKHNH\UHJXODWRURI*WR0WUDQVLWLRQDQGRQVHWRIPLWRVLVDQG UHJXODWHVWRDOHVVHUH[WHQW6WR*WUDQVLWLRQ_{:HHUHJXODWHV&'.DFWLYLW\WKURXJK}

<SKRVSKRU\ODWLRQ WKHUHE\ SUHYHQWLQJ SUHPDWXUH &'. DFWLYDWLRQ DQG PLWRWLF HQWU\$VPRVWSUHPDOLJQDQWFHOOVDOVRKDYHJHQHWLFFKDQJHVLQTP53 and CDKN2A5_ZH TXHVWLRQHGZKHWKHUSUHFDQFHURXVFHOOVIDFHFRPSDUDEOHSUREOHPVLQUHSOLFDWLRQDQGFHOO F\FOHUHJXODWLRQDV+16&&FHOOVDQGUHVSRQGFRPSDUDEO\WR:HHLQKLELWLRQ7KHUHIRUH ZHLQYHVWLJDWHGFHOOF\FOHSURJUHVVLRQDIWHUKRI:HHLQKLELWLRQ)LJXUHKMDQG6H

Figure 2: siRNA validations of siWEE1. a–e. 'HFRQYROXWLRQRIWKH60$57SRROLQWKHIRXUVHSDUDWH VL51$V DOO WDUJHWLQJ :(( LQ a 98SUH6&&0 SUHFDQFHURXV FHOO OLQH LQ EOXH b WKH SULPDU\ RUDOÀEUREODVWVLQJUHHQc806&&$d986&&DQGe986&&2(DOO+39QHJDWLYH +16&&OLQHVLQUHG$OOJUDSKVVKRZWKHHͿHFWRQFHOOYLDELOLW\XSRQNQRFNGRZQFRPSDUHGWRWKH QHJDWLYHWUDQVIHFWLRQFRQWUROXVHG1HJDWLYHWUDQVIHFWLRQFRQWUROVL&21752/ZDVXVHGIRUSUL PDU\ÀEUREODVWV806&&$DQG986&&2(6LQFHWR[LFLW\ZDVREVHUYHGZLWKVL&21752/ WUDQVIHFWLRQLQ98SUH6&&0DQG986&&VLLUC and siHPRT1ZHUHXVHGUHVSHFWLYHO\ZKLFK ZHUHVHWDWFHOOYLDELOLW\f.7KH:HHSURWHLQOHYHOVZHUHH[DPLQHGRQ:HVWHUQEORWDQGUHYHD OHGDQHDUFRPSOHWHNQRFNGRZQIRUWKHVL:((60$57SRRODQGVL:((DQGVL:((DQG VKRZHGDUHGXFHGOHYHORI:HHSURWHLQH[SUHVVLRQKSRVWWUDQVIHFWLRQ.QRFNGRZQHͿHFWVRQ :HHSURWHLQOHYHOFRUUHODWHGZLWKWKHYLDELOLW\HͿHFWVDVIRXQGLQ)LJXUHF1HJDWLYHWUDQVIHFWLRQ FRQWUROVVL&21752/DQGVLLUCZHUHWDNHQDORQJIRUFRPSDULVRQZLWKXQWUDQVIHFWHGFHOOV

7R IXUWKHU YDOLGDWH WKH SRWHQWLDO RI :HH LQKLELWLRQ DV D FKHPRSUHYHQWLYH WKHUDS\ DSDQHORISUHPDOLJQDQWFHOOFXOWXUHVZDVWUHDWHGZLWK$GDYRVHUWLEWRJHWKHUZLWKD SDQHORI+16&&DQGWZRRYDULDQWXPRUFHOOOLQHVDVUHIHUHQFHVLQFHRYDULDQFDQFHULV NQRZQWREHYXOQHUDEOHWR:HHLQKLELWLRQLQFOLQLFDOVWXGLHV_{7KHWHVWHGFHOOOLQHVDOO} KDUERUHGD

TP53

PXWDWLRQ7DEOH63ULPDU\QRQWUDQVIRUPHGRUDOÀEUREODVWVDQG NHUDWLQRF\WHVIURPKHDOWK\GRQRUVVHUYHGDVWR[LFLW\FRQWUROVWRLQGLFDWHDSRWHQWLDO WKHUDSHXWLFZLQGRZFRPSDUHGWRSUHPDOLJQDQWDQGWXPRUFHOOV$OO+16&&WXPRU FHOOOLQHVDQGSUHPDOLJQDQWFHOOVUHVSRQGHGLQFRPSDUDEOHFRQFHQWUDWLRQUDQJHVDV WKHWHVWHGRYDULDQWXPRUFHOOOLQHV29&$5DQG6.29RUZHUHHYHQPRUHVHQVLWLYH )LJXUH DJ DQG 6FH 7KH WHVWHG SULPDU\ RUDO FHOOV GLG QRW UHVSRQG WR :HH LQKLELWLRQRUDWOHDVWDWPXFKKLJKHUFRQFHQWUDWLRQV3ULPDU\ÀEUREODVWVIURPWZR

 

4

bLQEOXH+39QHJDWLYH+16&&FHOOOLQH806&&$cLQUHGSULPDU\RUDOÀEUREODVWV DQGNHUDWLQRF\WHVd-eERWKLQJUHHQDQGRYDULXPFDQFHUFHOOOLQH29&$5DVUHIHUHQFHf, in SXUSOH$OOJUDSKVGLVSOD\WKHUHODWLYHFHOOYLDELOLW\FRPSDUHGWRXQWUHDWHGFHOOVXSRQLQFUHDVLQJ FRQFHQWUDWLRQVRIWKHLQKLELWRUDIWHUKRIH[SRVXUH5HODWLYHFHOOYLDELOLW\WRXQWUHDWHGFHOOVLV VKRZQIRUDVHULDOGLOXWLRQRI$GDYRVHUWLEDWORJDULWKPLF[D[LVDQGWKHYLDELOLW\RIWKHXQWUHDWHG FHOOVSUHVHQWHGDVUHODWLYHFHOOYLDELOLW\RILVLPSXWHGDWS0$ODUJHUFHOOOLQHSDQHOLV SUHVHQWHGLQ)LJXUH6FHg.2YHUYLHZRIWKH(&YDOXHV—0RIDOOFHOOOLQHVWHVWHGH[FHSWWKH ÀEUREODVWV7KHSXUSOHOLQHVUHSUHVHQWWKHUHIHUHQFHRYDULDQWXPRUFHOOOLQHVDQGWKHJUHHQOLQHVWKH ECYDOXHVRIWKHSULPDU\NHUDWLQRF\WHFXOWXUHV7KHPDMRULW\RI+16&&DQGSUHPDOLJQDQWFHOOV DUHHTXDOO\RUHYHQPRUHYXOQHUDEOHWR$GDYRVHUWLEFRPSDUHGWRERWKRYDULDQWXPRUOLQHVWHVWHG h–j.&HOOF\FOHGLVWULEXWLRQRISUHFDQFHURXVFHOOOLQHV98SUH6&&0hDQG'iDQG+16&& FHOOOLQH806&&$jDIWHUKWUHDWPHQWZLWK$GDYRVHUWLE98SUH6&&0ZDVSXOVHGZLWK (G8IRUPLQDQGVXEVHTXHQWO\WKH'1$FRQWHQWZDVVWDLQHGZLWK'$3,XVLQJWKH&OLFN,7 PHWKRG$OORWKHUFHOOOLQHVLQFOXGLQJWKRVHVKRZQLQ)LJXUH6HZHUHSXOVHGZLWK%UG8IRUPLQ DQG'1$FRQWHQWZDVPHDVXUHGXVLQJ3,%RWKSUHFDQFHURXVDQGWXPRUFHOOVVKRZHGDEHUUDQWFHOO F\FOHGLVWULEXWLRQV %RWKSUHPDOLJQDQWFHOOOLQHV98SUH6&&0DQG'VKRZHGDQLQFUHDVHG6SKDVH SRSXODWLRQDIWHUKRI:HHLQKLELWLRQDOWKRXJK98SUH6&&0KDGDQLQFUHDVHLQ UHSOLFDWLQJ6SKDVH(G8SRVLWLYHFHOOVDQG'LQQRQUHSOLFDWLQJ6SKDVH%UG8 QHJDWLYH FHOOV ,Q IDFW DOO WHVWHG +16&& DQG 29&$5 FHOO OLQHV H[FHSW 806&& $DQG806&&&VKRZHGDQLQFUHDVHGSRSXODWLRQRIQRQUHSOLFDWLQJ6SKDVH FHOOVDWEDVHOLQHZKHQFRPSDUHGWRWKHSUHPDOLJQDQWFHOOVLPSO\LQJDPRUHVHYHUH FHOOF\FOHGLVUXSWLRQDWEDVHOLQH$IWHUWUHDWPHQWDPDMRULW\RIFHOOOLQHVLQWKLVSDQHO VKRZHG DQ 6SKDVH LQFUHDVH ' 98SUH6&&0 806&&$ 806&&& 806&&% 986&& 806&& DQG 6.29 ZKLOH WZR OLQHV GLVSOD\HG D * LQFUHDVH 986&& DQG 29&$5 ZKLFK VHHPHG WR UHODWH WR VHQVLWLYLW\ WR $GDYRVHUWLEDVWKHODWWHUWZRDUHOHVVVHQVLWLYH

Wee1 inhibition initiates death in mitosis and micro-nucleation due to DNA damage induction and unsupervised entry of mitosis

6LQFH :HH LV D PDLQ LQKLELWRU RI &'. ZKLFK FRQWUROV PLWRVLV WKH PROHFXODU DFWLYDWLRQRIDQXPEHURINH\UHJXODWRUVRIPLWRVLVZDVIXUWKHULQYHVWLJDWHG)LJXUH DG DQG 6DF ([SUHVVLRQ OHYHOV RI &'. DQG LWV ELQGLQJ SDUWQHU F\FOLQ % QRW VKRZQ UHPDLQHG PRUH RU OHVV VWDEOH XSRQ :HH LQKLELWLRQ DOWKRXJK WKH ODUJH QXPEHURIG\LQJFHOOVDIWHUKRIWUHDWPHQWPLJKWKDYHKDPSHUHGLQWHUSUHWDWLRQRI WKHGDWD8SRQWUHDWPHQWZLWKQ0$GDYRVHUWLEWKHLQKLELWRU\SKRVSKRU\ODWLRQ RI < RQ &'. GHFUHDVHG FRQÀUPLQJ HͿHFWLYH :HH LQKLELWLRQ )XUWKHUPRUH LQGXFWLRQRI'1$GDPDJHPDUNHUո+$[6HUZDVREVHUYHGLQERWKSUHPDOLJQDQW FHOOVDQGWXPRUFHOOOLQHVDIWHU$GDYRVHUWLEH[SRVXUHLQGLFDWLQJWKDWWKHORVVRI:HH DFWLYLW\ LPSDFWV UHSOLFDWLRQ VWUHVV DQG DVVRFLDWHG '1$ GDPDJH RU LPSDLUV '1$ UHSDLUVLJQDOLQJ7DNHQWRJHWKHUFDQFHUFHOOVWKDWDUHLQ6SKDVHRULQ*SKDVHHQWHU PLWRVLVSUHPDWXUHO\E\:HHLQKLELWLRQZKLFKOHDGVWRPLWRWLFIDLOXUHLQOLQHZLWK WKHFHOOF\FOHGLVWULEXWLRQXSRQ:HHLQKLELWLRQ

a

c

g

b

d

e

f

h

i

j

g

Figure 3: (;HFWVRQFHOOYLDELOLW\DQGFHOOF\FOHGLVWULEXWLRQXSRQ:HHLQKLELWLRQZLWKWKH clinically relevant inhibitor Adavosertib. a–f. Line graphs representing the dose responses XSRQK$GDYRVHUWLEWUHDWPHQWDUHVKRZQIRUSUHPDOLJQDQWFHOOV98SUH6&&0aDQG'

 

4

1H[WZHLQYHVWLJDWHGDEQRUPDOLWLHVLQPLWRWLFFHOOVLQSUHFDQFHURXV98SUH6&&0 DQG+16&&806&&$FHOOVDIWHUKRI:HHLQKLELWLRQ0LFURWXEXOHVDQGVSLQGOH IRUPDWLRQZHUHYLVXDOL]HGXVLQJն7XEXOLQJUHHQDQG'1$ZDVVWDLQHGZLWK'$3, EOXH)LJXUHHI,QXQWUHDWHGFRQGLWLRQVERWKSUHPDOLJQDQWDVZHOODV+16&& FHOOVVKRZHGQRUPDOELSRODUVSLQGOHVDQGFKURPRVRPDOFRQGHQVDWLRQGXULQJPLWRVLV $IWHU :HH LQKLELWLRQ WKH VSLQGOHV VKRZHG DEQRUPDOLWLHV DQG WKH FKURPRVRPHV IDLOHGWRDOLJQLQWKHPHWDSKDVHSODWH%RWKJLDQWFHOOVZLWKIUDJPHQWHG'1$DUURZV DQGLVRODWHG'1$QXFOHLDSSHDUHGIUHTXHQWO\LQGLFDWLQJPLWRWLFIDLOXUH5HPDUNDEO\ XSRQWUHDWPHQWZLWKQ0$GDYRVHUWLEZHREVHUYHGDVLJQLÀFDQWLQFUHDVHLQWKH VSLQGOHSROHWRSROHGLVWDQFHLQSURPHWDSKDVHFHOOVFRPSDUHGWRXQWUHDWHGFHOOV IRUERWK98SUH6&&0WZRVLGHGt test, P DQG806&&$WZRVLGHG

t test, P )LJXUHJKDQG6G7KLVLQGLFDWHVPLWRWLFDUUHVWGXHWR6$& FKHFNSRLQWDFWLYDWLRQLQZDUGIRUFHVRQWKHVSLQGOHVGXHWR'1$GDPDJHFDXVHGE\ :HHLQKLELWLRQDQGVSLQGOHH[KDXVWLRQ²_{7KHWUHDWPHQWFRQGLWLRQZLWKQ0} $GDYRVHUWLEZDVDOUHDG\WRRWR[LFDQGGLGQRWFRQWDLQHQRXJKSURPHWDSKDVHVIRU IXUWKHUDQDO\VLV DISCUSSION

:H UHVFUHHQHG D SUHYLRXVO\ LGHQWLÀHG SDQHO RI VL51$ 60$57SRROV WKDW WDUJHW HVVHQWLDO JHQHV LQ WZR FDQFHU FHOO OLQHV :H FRXOG FRQÀUP  RI WKH SUHYLRXVO\ LGHQWLÀHGJHQHVDVHVVHQWLDOLQDODUJHFHOOOLQHSDQHORIGLͿHUHQW+16&&VXEFODVVHV REWDLQLQJLQVLJKWLQSRVVLEOHQHZWDUJHWVIRUWKHUDS\RISUHFDQFHURXVFHOOVDVZHOODV +39QHJDWLYH+39SRVLWLYHDQG)$GHULYHGWXPRUV_{2IWKHFRQÀUPHGOHWKDOVL51$V}

WDUJHWFRUHHVVHQWLDOJHQHVRIZKLFKNQRFNGRZQLVDOVROHWKDOIRUSULPDU\RUDO ÀEUREODVWV_{EXWVHHPFDQFHUFHOOVSHFLÀFLQGLFDWLQJWKHRSSRUWXQLWLHVIRUWXPRU}

VSHFLÀF WDUJHWLQJ +RZHYHU EURDG DSSOLFDWLRQ LV FRPSOLFDWHG E\ WKH REVHUYDWLRQ WKDW UHVSRQVHV YDULHG FRQVLGHUDEO\ EHWZHHQ FHOO OLQHV$OWKRXJK WKLV OLNHO\ UHÁHFWV WKH LQWHUWXPRUDO KHWHURJHQHLW\ RI +16&&_{ LW GHPDQGV FOLQLFDO GHYHORSPHQW RI}

LQKLELWRUVLQSDUDOOHOZLWKFRPSDQLRQGLDJQRVWLFELRPDUNHUVIRUSDWLHQWVHOHFWLRQ_.

1XPHURXV QRYHO FDQGLGDWH FDQFHU JHQHV KDYH EHHQ LGHQWLÀHG E\ WKH VHTXHQFLQJ RI RYHU  +16&&V E\ WKH 7&*$ FRQVRUWLXP ZKLFK DJDLQ VWUHVVHV WKH LQWHU WXPRUDOKHWHURJHQHLW\RIWKHGLVHDVHGHVSLWHWKDWLWGHYHORSVIURPMXVWRQHFHOOW\SH LQRQHWLVVXH_{'LVDSSRLQWLQJO\WKHVHTXHQFLQJHͿRUWVDOVRGHPRQVWUDWHGWKHODFNRI}

GUXJJDEOH RQFRJHQLF PXWDWLRQV 1RQHWKHOHVV WKH PDQ\ PXWDWHG JHQHV DV ZHOO DV WKHPXOWLSOHFKURPRVRPDODEHUUDWLRQVPD\IRUPDVRXUFHIRUGUXJJDEOHWDUJHWVE\ V\QWKHWLFRUFROODWHUDOOHWKDOLW\:HLGHQWLÀHGPDQ\PRUHOHWKDOKLWVLQWKHVFUHHQHG WXPRU FHOO OLQHV WKDQ LQ WKH SULPDU\ RUDO FHOOV 7KH DVVRFLDWLRQ RI WKHVH HVVHQWLDO

a

e

g

b

g

c

d

h

f

)LJXUH(;HFWVRI:HHLQKLELWLRQRQFHOOF\FOHUHJXODWLRQ'1$GDPDJHDQGPLWRVLVD²G:HV WHUQEORWDQDO\VLVRISUHPDOLJQDQWFHOOOLQHV98SUH6&&0aDQG'b+16&&FHOOOLQH80 6&&$cDQGRYDULDQFHOOOLQH29&$5dDOOVKRZHGGHFUHDVHGS&'.<H[SUHVVLRQXSRQ WUHDWPHQW ZLWK  Q0$GDYRVHUWLE DOUHDG\ DIWHU K RI WUHDWPHQW c ,QFUHDVHG OHYHOV RI ո+$[ 6HULQGLFDWHG'1$GDPDJHLQGXFHGE\:HHLQKLELWLRQ$GGLWLRQDOFHOOOLQHVDUHVKRZQLQ)L JXUH6D²Fe-f.3UHFDQFHURXVFHOOV98SUH6&&0eDQG+16&&806&&$fZHUHVWDLQHGIRU նWXEXOLQPLFURWXEXOHVLQJUHHQDQG'1$'$3,LQEOXH,QXQWUHDWHGFRQGLWLRQVERWKWKHSUH PDOLJQDQWDQGWXPRUFHOOOLQHVVKRZHGQRUPDOELSRODUVSLQGOHIRUPDWLRQZLWKFRQGHQVDWHGFKURPR VRPHV8SRQWUHDWPHQWZLWKQ0$GDYRVHUWLEIRUKSURPHWDSKDVHFHOOVVKRZHGOHVVGHQVH VSLQGOHVZLWKSUREOHPDWLF'1$DOLJQPHQWDVZHOODVWULSRODUVSLQGOHVDQGPLFURQXFOHLIRUPDWLRQLQ 806&&$$IWHUWUHDWPHQWZLWKQ0$GDYRVHUWLEFKURPRVRPDODOLJQPHQWDQGFRQGHQVDWLRQ ZDVLQFUHDVLQJO\DEQRUPDOLQERWKFHOOOLQHVDQGJLDQWFHOOVZLWKPXOWLSOHQXFOHLRUQXFOHLIUDJPHQ WDWLRQZHUHIRXQGDUHVXOWRIPLWRWLFIDLOXUH1RPRQRSRODUVSLQGOHVZHUHIRXQGg-h. To investi JDWHPLWRWLFH[KDXVWLRQGXHWR6$&FKHFNSRLQWDFWLYDWLRQSROHWRSROHOHQJWK—PZDVPHDVXUHGRI SURPHWDSKDVHVLQXQWUHDWHGDQGQ0$GDYRVHUWLEWUHDWHGFHOOV$VLJQLÀFDQWLQFUHDVHRISROH WRSROHOHQJWKZDVIRXQGLQERWK98SUH6&&0JWZRVLGHGt test, P  DQG806&&$ hWZRVLGHGt test, P VHH)LJXUH6GIRUDUHSUHVHQWDWLYHSLFWXUH

 

4

WUDQVIRUPHG +16&& FDQFHU FHOO OLQHV DQG GHPRQVWUDWHG FRPSDUDEOH PLWRWLF IDLOXUHV²_{7KHFKHPRSUHYHQWLYHSRWHQWLDORI:HHLQKLELWRUVFRXOGEHLQYHVWLJDWHG}

LQSDWLHQWVZLWKDQHU\WKUROHXNRSODNLDOHVLRQWKDWKDUERUJHQHWLFFKDQJHVVXFKDVS DQGSORVVHV_{,QDGGLWLRQLWFRXOGEHDSSOLHGDVDGMXYDQWFKHPRSUHYHQWLYHWKHUDS\}

DIWHU VXUJLFDO UHVHFWLRQ LQ +16&& SDWLHQWV ZLWK G\VSODVWLF DQG JHQHWLF FKDQJHV LQ WKHVXUJLFDOPDUJLQVWRSUHYHQWORFDOUHFXUUHQFHDQGVHFRQGSULPDU\WXPRUV5_{. In a} SKDVH,,,VWXG\DQLQWHUPHGLDWHHQGSRLQWFRXOGEHH[SORLWHGVXFKDVVKULQNDJHRI WKHOHVLRQZLWKSKRWRGRFXPHQWDWLRQRUDXWRÁXRUHVFHQFHDQGDOVRE\KLVWRORJ\DQG JHQHWLFFKDQJHVLQELRSVLHVDQGEUXVKHGVDPSOHV²_{,QDVXEVHTXHQWSKDVH,,,VWXG\} WKHH΀FDF\LQWHUPVRIFDQFHUSUHYHQWLRQFRXOGEHHYDOXDWHGDVHQGSRLQW ,QFRQFOXVLRQZHVKRZWKDWWKHUHLVDPXOWLWXGHRIGUXJJDEOHWDUJHWVIRUVTXDPRXV FDQFHUDQGSUHPDOLJQDQWFHOOVGHVSLWHWKHIDFWWKDW+16&&LVDWXPRUVXSSUHVVRU gene driven disease_{$QH[FHOOHQWDQGSURPLVLQJGUXJWDUJHWIRUERWKWKHWXPRUVDQG}

WKHSUHFDQFHURXVÀHOGVLV:HHOLNHNLQDVHH΀FLHQWO\WDUJHWHGE\$GDYRVHUWLE7KH UHZLULQJRIFHOOF\FOHFRQWUROE\WKHIUHTXHQWLQDFWLYDWLRQRI

TP53

and

CDKN2A

in HDUO\ FDUFLQRJHQHVLV RI +16&& LV DQ H[FHOOHQW DSSURDFK IRU WDUJHWHG WUHDWPHQW RI WXPRUVDQGSUHFDQFHURXVPXFRVDOFKDQJHV

MATERIALS AND METHODS Cell culture

8VH RI UHVLGXDO WLVVXH VDPSOHV ZDV FDUULHG RXW DFFRUGLQJ WR WKH JXLGHOLQHV RI WKH 'XWFK0HGLFDO6FLHQWLÀF6RFLHWLHVZZZIHGHUDRUJ7KHVWXGLHVZLWKH[WUDELRSVLHV ZHUH DSSURYHG E\ WKH ,QVWLWXWLRQDO 5HYLHZ %RDUG RI $PVWHUGDP 80& ORFDWLRQ 98PF DQG SDWLHQW VSHFLPHQ ZHUH XVHG DIWHU ZULWWHQ LQIRUPHG FRQVHQW 3ULPDU\ FHOOVZHUHFROOHFWHGIURPH[FLVHGXYXODVRIKHDOWK\DGXOWVDVSUHYLRXVO\GHVFULEHG_.

7KH ÀEUREODVWV ZHUH FXOWXUHG LQ 'XOEHFFR·V 0RGLÀHG (DJOH·V 0HGLXP '0(0 /RQ]D %() ZLWK  IHWDO ERYLQH VHUXP )%6 %LRORJLFDO ,QGXVWULHV  $ DQG  PPRO/ /JOXWDPLQH /RQ]D %() 3ULPDU\ NHUDWLQRF\WHV DQG 98SUH6&&0 FHOOV ZHUH FXOWXUHG LQ VHUXPIUHH .*0 PHGLXP .*06)0 *LEFRVXSSOHPHQWHGZLWK%6$03%LRPHGLFDOVPJ ERYLQHSLWXLWDU\H[WUDFW*LEFR—JKXPDQUHFRPELQDQW(*)*LEFR —J$PSKRWHULFLQ%*LEFRDQG—J*HQWDP\FLQ6LJPD $OGULFK * ' ' DQG ' ZHUH REWDLQHG IURP 3URI . ' +XQWHU_and

FXOWXUHGLQ'0(0VXSSOHPHQWHGZLWK)%6PPRO//*OXWDPLQHðï _M

,QVXOLQ6LJPD,ðï_{0+\GURFRUWLVRQH6LJPD+DQG—J/(*)}

,QYLWURJHQ3+* JHQHVZLWKWKHJHQHWLFFKDQJHVLQWKHVHWXPRUFHOOVVXJJHVWWKDWFROODWHUDOOHWKDOLW\

GRHVSURYLGHDQRYHOVWUDWHJ\WRLGHQWLI\YXOQHUDELOLWLHV_{8SRQWKHORVVRIDERQD}

ÀGH WXPRU VXSSUHVVRU JHQH WKURXJK JHQHWLF DEHUUDWLRQV D QHLJKERULQJ SDVVHQJHU JHQHLVRIWHQKRPR]\JRXVO\RUKHWHUR]\JRXVO\ORVWDVZHOO7KHVHQHLJKERULQJJHQH ORVVHVZHUHFRQVLGHUHGIXWLOHEXWLQUHFHQWVWXGLHVLWKDVEHHQGHPRQVWUDWHGWKDWWKH JHQHVORFDWHGDWWKHVHORFLPD\SOD\LPSRUWDQWUROHVLQDYDULHW\RINH\PHWDEROLFDQG UHJXODWRU\IXQFWLRQVDQGWKHVXEVHTXHQWGHFUHDVHLQH[SUHVVLRQFDQEHH[SORLWHGDV WUHDWPHQWVWUDWHJ\_{)XUWKHULQYHVWLJDWLRQRIFROODWHUDOOHWKDOKLWVFRXOGOHDGWRWKH} LGHQWLÀFDWLRQRIIXWXUHWDUJHWVIRUWKHUDS\_. %HVLGHVRSWLRQVIRUWXPRUWUHDWPHQWZHLGHQWLÀHGJHQHWDUJHWVIRUFKHPRSUHYHQWLYH WUHDWPHQW RI SUHPDOLJQDQW FKDQJHV 7KH QXPEHU RI WDUJHWV IRU WUHDWPHQW RI SUHPDOLJQDQW FHOOV LV UHODWLYHO\ ORZ OLNHO\ DVVRFLDWHG ZLWK WKH VPDOOHU QXPEHU RI genetic changes_{1HYHUWKHOHVVWKHUHDUHSURPLVLQJFDQGLGDWHVVXFKDV3/.}_and

:HHOLNHNLQDVHDVSUHVHQWHGLQWKLVVWXG\ :HHLVDQLPSRUWDQWQHJDWLYHUHJXODWRURI&'.DQGFULWLFDOO\IRUFRUUHFWHQWU\LQWR PLWRVLVDWWKHHQGRI*SKDVH_{. In a}

_TP53

_{PXWDWHGEDFNJURXQG:HHLVWKRXJKWWR} EHLQYROYHGLQ6SKDVHUHJXODWLRQDVZHOOWKURXJK&'.UHJXODWLRQ25_{,QRXUGDWDZH} QRWHGDIWHU:HHLQKLELWLRQDYDULHW\RIFKDQJHVLQFHOOF\FOHFRQWURO'1$GDPDJH DQGDEQRUPDOPLWRVLV7KLVFOHDUO\VXJJHVWVDNH\UROHRI:HHLQ+16&&FHOOVDQG LQYROYHPHQW RI :HH LQ VTXDPRXV SUHFDQFHU FHOO F\FOH UHJXODWLRQ 8QH[SHFWHGO\ UHVSRQVHVWR$GDYRVHUWLEGLͿHUHGEHWZHHQSULPDU\NHUDWLQRF\WHVDQGÀEUREODVWV

in

vitro

,WKDVEHHQUHSRUWHGWKDW$GDYRVHUWLEWDUJHWVWKH<HVW\URVLQHNLQDVHZLWKWR IROGOHVVSRWHQF\22_{2WKHUVUHSRUWHGWKDW<HVNQRFNGRZQLQFUHDVHVSUROLIHUDWLRQDQG}

PLJUDWLRQLQÀEUREODVWVSRWHQWLDOO\H[SODLQLQJWKHVOLJKWLQFUHDVHLQYLDELOLW\LQWKH WHVWHG ÀEUREODVWV_{ ,QWHUHVWLQJO\ ZH FRPSDUHG WKH VHQVLWLYLW\ WR :HH LQKLELWLRQ}

in a

TP53

ZLOGW\SH+16&&FHOOOLQHDQGDIWHU

TP53

&5,635&DVNQRFNRXWDQG QRGLͿHUHQFHLQYXOQHUDELOLW\ZDVREVHUYHGVXJJHVWLQJDVRPHZKDWPRUHFRPSOH[ LQWHUDFWLRQ ZLWK PXWDWHG

TP53

15_{. 7KH DYDLODEOH LQKLELWRU $GDYRVHUWLE FXUUHQWO\} XVHGLQVHYHUDOFOLQLFDOWULDOVLQFRPELQDWLRQZLWKRWKHUGUXJVLVUHSRUWHGWREHZHOO WROHUDWHG ZLWK IDWLJXH QDXVHD WKURPERF\WRSHQLD DQG GLDUUKHD DV PRVW FRPPRQ adverse events²_{ )LUVW UHVXOWV DV VLQJOH DJHQW RU ZKHQ XVHG LQ D FRPELQDWLRQ}

WKHUDS\VHHPSURPLVLQJZLWKDQRYHUDOOUHVSRQVHUDWHRIZKHQFRPELQHGZLWK FDUERSODWLQLQDSKDVH,,VWXG\LQSDWLHQWVZLWK

TP53

PXWDWHGRYDULDQFDQFHU_{. In a}

UHFHQWQHRDGMXYDQWVWXG\LQ+16&&SDWLHQWVLQLWLDOUHVSRQVHVZKHQFRPELQHGZLWK SODWLQXPDQG)8ZHUHDOVRSURPLVLQJ_.

+HUH ZH VKRZ WKDW $GDYRVHUWLE LV HͿHFWLYH LQ SUHPDOLJQDQW FHOOV DV ZHOO +HQFH :HH LQKLELWLRQ PRQRWKHUDS\ FRXOG ZHOO VHUYH DV FKHPRSUHYHQWLYH VWUDWHJ\ WR HUDGLFDWH SUHFDQFHURXV FKDQJHV DQG SUHYHQW FDQFHU DQG ORFDO UHODSVH ,PSRUWDQWO\ SUHPDOLJQDQW FHOOV ZHUH FRPSDUDEO\ VHQVLWLYH WR :HH LQKLELWLRQ DV WKH IXOO\

 

4

VRXUFH*DPPDFHOO0'61RUGLRQ:KHQZHOOVUHDFKHGFRQÁXHQF\DWGD\  FHOOV ZHUH À[HG XVLQJ  SDUDIRUPDOGHK\GH 6LJPD$OGULFK 3 IRU PLQ DQGVWDLQHGIRUPLQXVLQJFU\VWDOYLROHW6LJPD$OGULFK&PJP/LQ+₂2 $IWHUGU\LQJFU\VWDOYLROHWDEVRUEDQFHZDVREWDLQHGE\DGGLQJDFHWLFDFLGIRU PLQDQGPHDVXULQJDEVRUEDQFHDWրQP

Cell cycle analysis

&HOOVZHUHVHHGHGLQD7ÁDVNDQGZKHQFRQÁXHQFHZDVUHDFKHGWUHDWHGIRU KZLWK$GDYRVHUWLE%HIRUHKDUYHVWFHOOVZHUHSXOVHGZLWKQPRO/EURPR GHR[\XUGLQH%UG86LJPD$OGULFK²IRUPLQWKHQKDUYHVWHGDQGÀ[HGLQ LFHFROG(W2+RYHUQLJKW1H[WFHOOVZHUHLQFXEDWHGZLWKPJP/51$VH$ SHUPHDELOL]HGZLWKPRO/+&O7ULWRQ;IRUPLQDQG+&OQHXWUDOL]HG ZLWKPRO/1D2BO%UG8ZDVVWDLQHGRYHUQLJKWDWƒ&ZLWKPRXVHDQWL%UG8 DQWLERG\FORQH%8D0'DNRDQGÁXRUHVFHLQLVRWKLRF\DQDWH),7&ODEHOHG ZLWK D FRQMXJDWHG UDEELW DQWLPRXVH DQWLERG\ ) 'DNR '1$ FRQWHQW ZDV VWDLQHGZLWKSURSLGLXPLRGLGH3,—J3,SHU_{FHOOV6LJPD$OGULFK3}

)RU 98SUH6&&0WKH &OLFNL7Œ(G8$OH[D )OXRUŒ  )ORZ &\WRPHWU\$VVD\ .LW 7KHUPR)LVKHU 6FLHQWLÀF & ZDV XVHG DFFRUGLQJ WR WKH SURWRFRO RI WKH PDQXIDFWXUHUDQG'1$ZDVVWDLQHGZLWKХGLDPLGLQRSKHQ\OLQGROH'$3, BD LSR II FortessaTM _{and BD FACSDiva}TM_{VRIWZDUH9%'%LRVFLHQFHVZHUHXVHG}

IRUÁRZF\WRPHWU\DQGGDWDDQDO\VLV

Western blot analysis

:KROHFHOOO\VDWHVZHUHREWDLQHGE\5,3$O\VLVDQGH[WUDFWLRQEXͿHU7KHUPR6FLHQWLÀF FRQWDLQLQJ[+$/7ŒSURWHDVHDQGSKRVSKDWDVHLQKLELWRU('7$IUHHFRFNWDLO 7KHUPR6FLHQWLÀF3URWHLQFRQWHQWZDVPHDVXUHGZLWK3LHUFHTM _{BCA Protein}

DVVD\7KHUPR6FLHQWLÀF1RUPDOL]HGZKROHFHOOO\VDWHVZHUHUXQRQ² SUHFDVWHG JUDGLHQW 6'63$*( JHOV %ROW %LV7ULV 3OXV JHOV ,QYLWURJHQ 1: XVLQJ0236RU0(6UXQQLQJEXͿHU$IWHUEORWWLQJZLWK7*EXͿHU%LR5DG 6XSHU6LJQDOŠ:HVW3LFR&KHPLOXPLQHVFHQW6XEVWUDWH7KHUPR6FLHQWLÀFZDV XVHGIRUGHYHORSPHQWRQ8YLWHF$OOLDQFHUHDGHU8YLWHF&DPEULGJHRU2G\VVH\Š &/[,PDJLQJ6\VWHP/L&25$QWLERGLHVXVHGDUHOLVWHGLQ7DEOH6 ,PPXQRÁXRUHVFHQWVWDLQLQJ 0LFURVFRSLFJODVVVOLGHVZHUHSUHSDUHGDVGHVFULEHGSUHYLRXVO\_{DQGSLFWXUHVZHUH}

REWDLQHG XVLQJ D /HLFD '0 $QDO\VLV DQG SROHWRSROH PHDVXUHPHQWV ZHUH SHUIRUPHGXVLQJ/$6$SSOLFDWLRQ6XLWH;YHUVLRQ/HLFD )D'X29&$5DQG6.29ZHUHREWDLQHGIURPWKH$PHULFDQ7\SH&XOWXUH&ROOHFWLRQ 7KHRWKHUXVHGFHOOOLQHVZHUHREWDLQHGDQGFXOWXUHGDVGHVFULEHGEHIRUH²_. $OOFHOOVZHUHFXOWXUHGZLWKRXWDQWLELRWLFVZHUHP\FRSODVPDQHJDWLYHDQGFKHFNHG UHJXODUO\0\FRDOHUW/RQ]D/7DQGZHUHDXWKHQWLFDWHGE\YLVXDOLQVSHFWLRQ DQGJHQHWLFSURÀOLQJRQLQGLFDWLRQ&HOOOLQHVZHUHFXOWXUHGWRDPD[LPXPRIIRXU PRQWKV DIWHU WKDZLQJ 7KH

TP53

PXWDWLRQ VWDWXV RI DOO SUHFDQFHURXV OLQHV DQG 29&$5DQG6.29ZHUHGHWHUPLQHGDVGHVFULEHGEHIRUH52_.

siRNA re-screen and data analysis

$ OLEUDU\ RI  OHWKDO VL51$ 60$57SRROV ZDV FXVWRPPDGH EDVHG RQ SUHYLRXV UHVXOWV_{$UUD\EDVHGUHVFUHHQLQJRIWKLVOLEUDU\DQGUHDGRXWRIFHOOYLDELOLW\ZDV} SHUIRUPHGLQDZHOOVSODWH*UHLQHU%LRRQHLQWULSOLFDWHIRUHYHU\FHOOOLQH DVGHVFULEHG7DEOH_{7KHGDWDZDV/RJWUDQVIRUPHGDQGQRUPDOL]HGIRUUHSOLFDWH} DQGSODWHHͿHFWVSHUFHOOOLQHXVLQJDOLQHDUUHJUHVVLRQPRGHOEDVHGRQWKHQHJDWLYH FRQWUROVSUHVHQWRQHYHU\SODWHVL&21752/'KDUPDFRQ'0HGLDQ YDOXHVRIWKHWULSOLFDWHVZHUHFDOFXODWHGWRGHWHUPLQHWKHHͿHFWRQYLDELOLW\SURYLGLQJ DYLDELOLW\VFRUHIRUHYHU\VL51$WHVWHG Collateral lethality /RZFRYHUDJHZKROHJHQRPHVHTXHQFLQJRIWKHFHOOOLQHVZDVSHUIRUPHGDVGHVFULEHG SUHYLRXVO\_{7KHREWDLQHG'1$FRS\QXPEHU&1GDWDDQGVL51$YLDELOLW\VFRUHV} ZHUHDQDO\]HGXVLQJWKHJHQHVHWPRGHODSSURDFK_{%ULHÁ\HDFK&1YDULDEOHDQG} YLDELOLW\VFRUHRIDOOVL51$VORFDWHGRQWKHVDPHFKURPRVRPHDUPZHUHDVVRFLDWHG 7KLVSURYLGHGDSYDOXHIRUHDFK&1YDULDEOHVXEVHTXHQWO\FRUUHFWHGIRUPXOWLSOH WHVWLQJXVLQJ%HQMDPLQL+RFKEHUJ·V)'5PHWKRG_. siRNA deconvolution VL51$GHFRQYROXWLRQZDVSHUIRUPHGDVSUHYLRXVO\GHVFULEHG7DEOH6_. Dose-response curves and combination therapies

KDIWHUVHHGLQJFHOOVLQDZHOOVPLFURSODWHLQDSUHGHWHUPLQHGFRQÁXHQF\WKH VPDOO PROHFXOH :HH LQKLELWRU $GDYRVHUWLE $='0. %LRYLVLRQ  RU 3$53 LQKLELWRU 7DOD]RSDULE $YRQ0HGFKHP$YRQ ZDV GLOXWHG LQ D VHULDO GLOXWLRQRIQ0WR—0IRUWXPRUFHOOOLQHVDQGSUHFDQFHURXVFHOOVDQGLQQ0 WR—0IRUSULPDU\FHOOV'062$IWHUKFHOOYLDELOLW\ZDVGHWHUPLQHG XVLQJ&HOO7LWHU%OXH3URPHJD*DQGD*OR0D[PLFURSODWHUHDGHU3URPHJD *0&HOOVZHUHWHVWHGWKUHHWLPHVLQWULSOLFDWH

)RU FRPELQDWLRQ H[SHULPHQWV ZLWK ոLUUDGLDWLRQ FHOOV ZHUH VHHGHG LQ D ZHOOV IRUPDWDWORZGHQVLW\LUUDGLDWHGDQGWUHDWHGZLWKWKHLQKLELWRUKODWHUXVLQJD_Co

 

4

REFERENCES  )HUOD\-6KLQ+5%UD\))RUPDQ'0DWKHUV&3DUNLQ'0(VWLPDWHVRIZRUOGZLGHEXUGHQRIFDQFHU LQ*/2%2&$1,QW-&DQFHU127²  /HHPDQV&5%UDDNKXLV%-0%UDNHQKRͿ5+7KHPROHFXODUELRORJ\RIKHDGDQGQHFNFDQFHUNat Rev Cancer11²  6FKHSPDQ.3YDQGHU0HLM(+6PHHOH/(YDQGHU:DDO0DOLJQDQWWUDQVIRUPDWLRQRIRUDOOHXNRSODNLD D IROORZXS VWXG\ RI D KRVSLWDOEDVHG SRSXODWLRQ RI  SDWLHQWV ZLWK RUDO OHXNRSODNLD IURP 7KH 1HWKHUODQGVOral Oncol34²

 5HLFKDUW3$3KLOLSVHQ+32UDOHU\WKURSODNLD$UHYLHZOral Oncol41²

 GH%RHU'9%ULQN$%XLM]H06WLJWHUYDQ:DOVXP0+XQWHU.'<OVWUD%et al. (VWDEOLVKPHQWDQG *HQHWLF/DQGVFDSHRI3UHFDQFHU&HOO0RGHO6\VWHPVIURPWKH+HDGDQG1HFN0XFRVDO/LQLQJMol Cancer Res17²  *UDYHODQG$3*ROXVLQVNL3-%XLM]H0'RXPD56RQV1.XLN'-et al./RVVRIKHWHUR]\JRVLW\DWS DQGSLPPXQRSRVLWLYLW\LQVXUJLFDOPDUJLQVSUHGLFWORFDOUHODSVHLQKHDGDQGQHFNVTXDPRXVFHOO carcinoma. ,QW-&DQFHU128²  7DERU03%UDNHQKRͿ5+5XLMWHU6FKLSSHUV+-.XPPHU-$/HHPDQV&5%UDDNKXLV%-*HQHWLFDOO\ DOWHUHGÀHOGVDVRULJLQRIORFDOO\UHFXUUHQWKHDGDQGQHFNFDQFHUDUHWURVSHFWLYHVWXG\Clin Cancer Res 10²

 /HHPDQV&56QLMGHUV3-)%UDNHQKRͿ5+7KHPROHFXODUODQGVFDSHRIKHDGDQGQHFNFDQFHUNat Rev

Cancer18²

 /DZUHQFH06RXJQH]&/LFKWHQVWHLQ/&LEXOVNLV./DQGHU(*DEULHO6et al. Comprehensive genomic FKDUDFWHUL]DWLRQRIKHDGDQGQHFNVTXDPRXVFHOOFDUFLQRPDVNature517²

 0XOOHU)/$TXLODQWL($'HSLQKR5$&ROODWHUDO/HWKDOLW\$1HZ7KHUDSHXWLF6WUDWHJ\LQ2QFRORJ\

Trends Cancer1

 0DUWHQVGH .HPS 65 1DJHO 5 6WLJWHUYDQ :DOVXP 0 YDQ 'HU 0HXOHQ ,+ YDQ %HXVHFKHP 9: %UDDNKXLV%-0et al. )XQFWLRQDOJHQHWLFVFUHHQVLGHQWLI\JHQHVHVVHQWLDOIRUWXPRUFHOOVXUYLYDOLQKHDG DQGQHFNDQGOXQJFDQFHUClin Cancer Res19²

 GH %RHU '9 0DUWHQVGH .HPS 65 %XLM]H 0 6WLJWHUYDQ :DOVXP 0 %ORHPHQD ( 'LHWULFK 5 et al. 7DUJHWLQJ3/.DVDQRYHOFKHPRSUHYHQWLYHDSSURDFKWRHUDGLFDWHSUHQHRSODVWLFPXFRVDOFKDQJHVLQ the head and neck. Oncotarget8²

 1DJHO50DUWHQVGH.HPS65%XLM]H0-DFREV*%UDDNKXLV%-0%UDNHQKRͿ5+Treatment response RI+39SRVLWLYHDQG+39QHJDWLYHKHDGDQGQHFNVTXDPRXVFHOOFDUFLQRPDFHOOOLQHVOral Oncol

49²

 0HQH]HV5;%RHW]HU06LHVZHUGD0YDQ2PPHQ*-%%RHU-0,QWHJUDWHGDQDO\VLVRI'1$FRS\ QXPEHUDQGJHQHH[SUHVVLRQPLFURDUUD\GDWDXVLQJJHQHVHWVBMC Bioinformatics10  YDQ+DUWHQ$03RHOO-%%XLM]H0%ULQN$:HOOV6,/HHPDQV&5et al. Characterization of a head and

QHFNFDQFHUGHULYHGFHOOOLQHSDQHOFRQÀUPVWKHGLVWLQFW73SURÀFLHQWFRS\QXPEHUVLOHQWVXEFODVV

Oral Oncol98²

 +DUW 7 &KDQGUDVKHNKDU 0$UHJJHU 0 6WHLQKDUW = %URZQ .5 0DF/HRG * et al. +LJK5HVROXWLRQ &5,6356FUHHQV5HYHDO)LWQHVV*HQHVDQG*HQRW\SH6SHFLÀF&DQFHU/LDELOLWLHVCell163² 

 +XDQJ ': 6KHUPDQ %7 /HPSLFNL 5$ %LRLQIRUPDWLFV HQULFKPHQW WRROV SDWKV WRZDUG WKH FRPSUHKHQVLYHIXQFWLRQDODQDO\VLVRIODUJHJHQHOLVWVNucleic Acids Res37²

 :DJQHU $+ &RͿPDQ $& $LQVFRXJK %- 6SLHV 1& 6NLGPRUH =/ &DPSEHOO .0 et al. '*,GE  PLQLQJFOLQLFDOO\UHOHYDQWGUXJJHQHLQWHUDFWLRQVNucleic Acids Res44'²'

Statistical analysis $OOVWDWLVWLFDODQDO\VHVZHUHSHUIRUPHGXVLQJ*UDSKSDG3ULVPYHUVLRQDQGRU5 YHUVLRQ7KHVWDWLVWLFDOSDFNDJH6,0YHUVLRQ_{ZDVXVHGIRUWKHLQWHJUDWHG} DQDO\VLVRIWKHFRS\QXPEHUDQGVL51$YLDELOLW\VFRUH ACKNOWLEDGEMENTS 7KHDXWKRUVZRXOGOLNHWRWKDQN$UMHQ%ULQN,GDYDQGHU0HXOHQ0XLOHPDQ*RYLQG 3DLDQG5LFKDUGYDQGHU0DVWIRUWKHLUFRQWULEXWLRQVWRWKLVPDQXVFULSW

 

4

 'R.:LOVNHU'-L-=ORWW-)UHVKZDWHU7.LQGHUV5-et al.3KDVH,VWXG\RIVLQJOHDJHQW$='0. DZHHNLQDVHLQKLELWRULQSDWLHQWVZLWKUHIUDFWRU\VROLGWXPRUV-&OLQ2QFRO33²  2VPDQ$$0RQURH002UWHJD$OYHV093DWHO$$.DWVRQLV3)LW]JHUDOG$/et al. :HH.LQDVH ,QKLELWLRQ2YHUFRPHV&LVSODWLQ5HVLVWDQFH$VVRFLDWHGZLWK+LJK5LVN730XWDWLRQVLQ+HDGDQG 1HFN&DQFHUWKURXJK0LWRWLF$UUHVW)ROORZHGE\6HQHVFHQFHMol Cancer Ther14²  7DQDND13DWHO$$7DQJ/6LOYHU1//LQGHPDQQ$7DNDKDVKL+et al.5HSOLFDWLRQVWUHVVOHDGLQJWR

DSRSWRVLVZLWKLQWKH6SKDVHFRQWULEXWHVWRV\QHUJLVPEHWZHHQYRULQRVWDWDQG$='LQ+16&& KDUERULQJKLJKULVN73PXWDWLRQClin Cancer Res23²

 7DQDND13DWHO$$:DQJ-)UHGHULFN0-.DOX11=KDR0et al.:HH.LQDVH,QKLELWLRQ6HQVLWL]HV +LJK5LVN +39 +16&& WR $SRSWRVLV $FFRPSDQLHG E\ 'RZQUHJXODWLRQ RI 0&O DQG ;,$3 Antiapoptotic Proteins. Clin Cancer Res21²

 =KDQJ/3RK&):LOOLDPV0/DURQGH'0%HUHDQ.*DUGQHU3-et al./RVVRIKHWHUR]\JRVLW\/2+ SURÀOHVYDOLGDWHGULVNSUHGLFWRUVIRUSURJUHVVLRQWRRUDOFDQFHUCancer Prev Res (Phila) 5² 

 3RK&)$QGHUVRQ':'XUKDP-6&KHQ-%HUHDQ.:0DF$XOD\&(et al.)OXRUHVFHQFH9LVXDOL]DWLRQ *XLGHG6XUJHU\IRU(DUO\6WDJH2UDO&DQFHU-$0$2WRODU\QJRO+HDG1HFN6XUJ142²  3RK&)=KDQJ/$QGHUVRQ':'XUKDP-6:LOOLDPV303ULGG\5:et al.)OXRUHVFHQFHYLVXDOL]DWLRQ

GHWHFWLRQRIÀHOGDOWHUDWLRQVLQWXPRUPDUJLQVRIRUDOFDQFHUSDWLHQWVClin Cancer Res12² 

 6PHWVHUV6(9HOOHXHU('LHWULFK5:X7%ULQN$%XLM]H0et al.1RQLQYDVLYHPROHFXODUVFUHHQLQJIRU RUDOSUHFDQFHULQ)DQFRQLDQHPLDSDWLHQWVCancer Prev Res (Phila)8²

 YDQ=HHEXUJ+-7*UDYHODQG$3%ULQN$1JX\HQ0/HHPDQV&5%ORHPHQD(et al.*HQHUDWLRQRI SUHFXUVRUFHOOOLQHVIURPSUHQHRSODVWLFÀHOGVVXUURXQGLQJKHDGDQGQHFNFDQFHUVHead Neck35 ²

 0F*UHJRU ) :DJQHU ( )HOL[ ' 6RXWDU ' 3DUNLQVRQ . +DUULVRQ 3 ,QDSSURSULDWH 5HWLQRLF $FLG 5HFHSWRUD([SUHVVLRQLQ2UDO'\VSODVLDV&RUUHODWLRQZLWK$FTXLVLWLRQRIWKH,PPRUWDO3KHQRW\SH

Cancer Res57²

 0F*UHJRU ) 0XQWRQL $ )OHPLQJ - %URZQ - )HOL[ '+ 0DF'RQDOG '* et al. 0ROHFXODU FKDQJHV DVVRFLDWHGZLWKRUDOG\VSODVLDSURJUHVVLRQDQGDFTXLVLWLRQRILPPRUWDOLW\SRWHQWLDOIRULWVUHYHUVDOE\ D]DF\WLGLQHCancer Res62²

 +HUPVHQ0$-$-RHQMH+$UZHUW):HOWHUV0-3%UDDNKXLV%-0%DJQD\0et al.&HQWURPHULFEUHDNDJH DVDPDMRUFDXVHRIF\WRJHQHWLFDEQRUPDOLWLHVLQRUDOVTXDPRXVFHOOFDUFLQRPDGenes, Chromosom Cancer 15²

 6WRHSNHU&$PH]LDQH1YDQGHU/HOLM3.RRL,(2RVWUD$%5RRLPDQV0$et al. Defects in the Fanconi $QHPLD3DWKZD\DQG&KURPDWLG&RKHVLRQLQ+HDGDQG1HFN&DQFHUCancer Res75²  YDQ =HHEXUJ +-7 6QLMGHUV 3-) 3DOV * +HUPVHQ 0$-$ 5RRLPDQV 0$ %DJE\ * et al. *HQHUDWLRQ

DQG0ROHFXODU&KDUDFWHUL]DWLRQRI+HDGDQG1HFN6TXDPRXV&HOO/LQHVRI)DQFRQL$QHPLD3DWLHQWV Cancer Res65²  0DUWHQVGH.HPS65'DOP68:LMQROWV)0-%ULQN$+RQH\ZHOO5-3HWHUV*-et al.'1$%RXQG 3ODWLQXP,VWKH0DMRU'HWHUPLQDQWRI&LVSODWLQ6HQVLWLYLW\LQ+HDGDQG1HFN6TXDPRXV&DUFLQRPD &HOOVPLoS One8H  %HQMDPLQL<+RFKEHUJ<&RQWUROOLQJWKH)DOVH'LVFRYHU\5DWH$3UDFWLFDODQG3RZHUIXO$SSURDFKWR 0XOWLSOH7HVWLQJ-56WDW6RF6HU%57²

 0DUWLQH]0RQWLHO 1 5RVDV0XUULHWD 1+ 5XL] 0$ 0RQMDUD]*X]PDQ ( 0DUWLQH]&RQWUHUDV 5 $OWHUQDWLYHVSOLFLQJDVDWDUJHWIRUFDQFHUWUHDWPHQW,QW-0RO6FL19

 /HLMHQ6YDQ*HHO50-06RQNH*6GH-RQJ'5RVHQEHUJ(+0DUFKHWWL6et al. 3KDVH,,VWXG\RI:(( LQKLELWRU$='SOXVFDUERSODWLQLQSDWLHQWVZLWKWSPXWDWHGRYDULDQFDQFHUUHIUDFWRU\RUUHVLVWDQW WRÀUVWOLQHWKHUDS\ZLWKLQPRQWKV-&OLQ2QFRO34²

 0pQGH](5RGULJXH]&3.DR0&5DMX6'LDE$+DUELVRQ5$et al.$3KDVH,&OLQLFDO7ULDORI$=' LQ&RPELQDWLRQZLWK1HRDGMXYDQW:HHNO\'RFHWD[HODQG&LVSODWLQEHIRUH'HÀQLWLYH7KHUDS\LQ+HDG DQG1HFN6TXDPRXV&HOO&DUFLQRPDClin Cancer Res24²

 +LUDL+,ZDVDZD<2NDGD0$UDL71LVKLEDWD7.RED\DVKL0et al.6PDOOPROHFXOHLQKLELWLRQRI :HHNLQDVHE\0.VHOHFWLYHO\VHQVLWL]HVSGHÀFLHQWWXPRUFHOOVWR'1$GDPDJLQJDJHQWVMol

Cancer Ther8²

 .DUQDN'(QJHONH&*3DUVHOV/$.DXVDU7:HL'5REHUWVRQ-5et al. &RPELQHG,QKLELWLRQRI:HH DQG3$53IRU5DGLRVHQVLWL]DWLRQLQ3DQFUHDWLF&DQFHUClin Cancer Res20²  /DO6=DUHL0&KDQG61'\OJMHUL(0DPEHOOL/LVERD1&3LVKYDLDQ0-et al.:((LQKLELWLRQLQ

SDQFUHDWLFFDQFHUFHOOVLVGHSHQGHQWRQ'1$UHSDLUVWDWXVLQDFRQWH[WGHSHQGHQWPDQQHU6FL5HS

6

 *HHQHQ --- 6FKHOOHQV -+0 0ROHFXODU SDWKZD\V 7DUJHWLQJ WKH SURWHLQ NLQDVH :HH LQ FDQFHU Clin

Cancer Res23²

 YDQ +DUWHQ $0 %XLM]H 0 YDQ GHU 0DVW 5 5RRLPDQV 0$ 0DUWHQVGH .HPS 65 %DFKDV & et al. 7DUJHWLQJWKHFHOOF\FOHLQKHDGDQGQHFNFDQFHUE\&KNLQKLELWLRQDQRYHOFRQFHSWRIELPRGDOFHOO death. Oncogenesis8  5KLQG15XVVHOO36LJQDOLQJSDWKZD\VWKDWUHJXODWHFHOOGLYLVLRQ&ROG6SULQJ+DUE3HUVSHFW%LRO 4D  1DQQDV1-0XUUD\$:7HWKHULQJ6LVWHU&HQWURPHUHVWR(DFK2WKHU6XJJHVWVWKH6SLQGOH&KHFNSRLQW 'HWHFWV6WUHWFKZLWKLQWKH.LQHWRFKRUHPLoS Genet10H

 :KU0&KHQ<'XPRQW6*URHQ$&1HHGOHPDQ'-6DOLF$et al. Evidence for an Upper Limit to 0LWRWLF6SLQGOH/HQJWKCurr Biol18²

 *DQHP1-3HOOPDQ'/LQNLQJDEQRUPDOPLWRVLVWRWKHDFTXLVLWLRQRI'1$GDPDJH-&HOO%LRO

199²

 GH5RHVW5+0HV6:3RHOO-%%ULQN$YDQGH:LHO0$%ORHPHQD(et al. 0ROHFXODU&KDUDFWHUL]DWLRQ RI/RFDOO\5HODSVHG+HDGDQG1HFN&DQFHUDIWHU&RQFRPLWDQW&KHPRUDGLRWKHUDS\Clin Cancer Res 25  9LVZDQDWKDQ651RJXHLUD0)%XVV&*.ULOO%XUJHU-0:DZHU0-0DOROHSV]D(et al.*HQRPHVFDOH DQDO\VLVLGHQWLÀHVSDUDORJOHWKDOLW\DVDYXOQHUDELOLW\RIFKURPRVRPHSORVVLQFDQFHUNat Genet 50²  1LMKDZDQ'=DFN7,5HQ<6WULFNODQG05/DPRWKH56FKXPDFKHU6(et al.&DQFHUYXOQHUDELOLWLHV XQYHLOHGE\JHQRPLFORVVCell150

 =KDR ' 'H3LQKR 5$ 6\QWKHWLF HVVHQWLDOLW\ 7DUJHWLQJ WXPRU VXSSUHVVRU GHÀFLHQFLHV LQ FDQFHU

%LRHVVD\V39.

 1XUVH3$MRXUQH\LQVFLHQFH&HOO&\FOHFRQWUROMol Med23²

 %RFNKROW60%XUULGJH.$QH[DPLQDWLRQRIIRFDODGKHVLRQIRUPDWLRQDQGW\URVLQHSKRVSKRU\ODWLRQLQ ÀEUREODVWVLVRODWHGIURP6UF)\QDQG<HVPLFHCell Adhes Commun3²

 &KDWWHUML 7 9DUNDULV $6 3DULNK 18 6RQJ -+ &KHQJ &- 6FKZHSSH 5( et al. <HVPHGLDWHG SKRVSKRU\ODWLRQ RI IRFDO DGKHVLRQ NLQDVH DW W\URVLQH  LQFUHDVHV PHWDVWDWLF SRWHQWLDO RI SURVWDWH FDQFHUFHOOVOncotarget6²

 

4

a

b

a

c

d

e

c

d

e

)LJXUH6+LWLGHQWLÀFDWLRQDQGGRVHUHVSRQVHVRIDGGLWLRQDO+16&&SUHFDQFHURXVDQGRYDULXP cancer cell lines treated with Adavosertib. a.'$9,'DQDO\VLVVKRZHGWKDWWKHWXPRUVSHFLÀF HVVHQWLDOJHQHVZHUHFODVVLÀHGLQVHYHQVXEJURXSVPLWRVLVKHOLFDVH51$SRO\PHUDVHWUDQVODWLRQDO LQLWLDWLRQSURWHDVRPHVSOLFHRVRPHDQGULERVRPHb.'$9,'DQDO\VLVRIWKHFRUHHVVHQWLDOJHQHV RI ZKLFK NQRFNGRZQ ZDV OHWKDO LQ +16&& DQG SULPDU\ FHOOV ZHUH IRXQG WR EH PDLQO\ ULERVRPH associated genes. c-e.7KHUHVSRQVHVWRK$GDYRVHUWLEWUHDWPHQWDUHVKRZQIRUDGGLWLRQDO+16&& FHOOOLQHVcSUHFDQFHURXVFHOOVdDQGDQRYDULDQFDQFHUFHOOOLQHeUHVSHFWLYHO\7KHUHODWLYHFHOO YLDELOLW\WRXQWUHDWHGFHOOVLVVKRZQIRUDVHULDOGLOXWLRQRI$GDYRVHUWLEDWWKHORJDULWKPLF[D[LVDQG WKHYLDELOLW\RIWKHXQWUHDWHGFHOOVUHSUHVHQWHGDVUHODWLYHFHOOYLDELOLW\RILVLPSXWHGDWS0 SUPPLEMENTARY DATA

a

c

b

c

Figure S1: Re-screening of 319 tumor-lethal siRNAs. a.2YHUYLHZRIWKHZRUNÁRZRIWKHUHVFUHHQ RI  VL51$ 60$57SRROV VHOHFWHG IURP WZR JHQRPHZLGH VL51$ VFUHHQV RQ DQ H[WHQGHG FHOO OLQHSDQHORIWZHOYHWXPRUFHOOOLQHVRQHSUHFDQFHURXVFHOOOLQHDQGWKUHHSULPDU\ÀEUREODVWFXOWX UHV1H[WGDWDDQDO\VLVDQGVHOHFWLRQUHYHDOHGOHWKDOVL51$VRIZKLFKZHUHWXPRUVSHFLÀF )XUWKHUDQDO\VLVUHYHDOHGGUXJJDEOHJHQHVRIZKLFKZHUHHVVHQWLDOLQWKHSUHFDQFHURXVFHOOVDV ZHOO7DUJHWHGWKHUDS\ZDVH[SORUHGE\FROODWHUDOOHWKDOLW\DVZHOODVYDOLGDWLRQRIRQHVSHFLÀFWDUJHW JHQH:((b.*UDSKLFDOSUHVHQWDWLRQRIWKHUHVFUHHQLQJRIWKHH[WHQGHGFHOOOLQHSDQHOZLWKWKH VL51$60$57SRROV&HOOVZHUHHLWKHUIRUZDUGO\WUDQVIHFWHGKDIWHUVHHGLQJRUUHYHUVHO\E\ WUDQVIHFWLQJFHOOVGXULQJVHHGLQJ$IWHUKRIVL51$WUDQVIHFWLRQFHOOYLDELOLW\ZDVPHDVXUHGXVLQJ &HOO7LWHU%OXHc.0HDQQXPEHURIOHWKDOVL51$60$57SRROVSHUJURXSRIFHOOOLQHV7KHSULPDU\RUDO ÀEUREODVWVVKRZHGRYHUWKUHHWLPHVOHVVOHWKDOKLWVFRPSDUHGWRWKH+16&&FHOOOLQHJURXSV

 

4

UHJXODWRUV RI FHOO F\FOH SURJUHVVLRQ 1R FRUUHODWLRQ ZDV IRXQG EHWZHHQ UHVSRQVHV WR LQKLELWLRQ RI &KNRU:HHLQGLFDWLQJWKDWVHQVLWLYLWLHVWRWKRVHGUXJVDUHEDVHGRQGLͿHUHQWPHFKDQLVPVd.&HOO OLQHVHQVLWLYLW\WRFLVSODWLQWUHDWPHQWGRHVQRWFRUUHODWHZLWKUHVSRQVHWR:HHLQKLELWLRQVXJJHVWLQJ WKDWSDWLHQWVQRWUHVSRQGLQJWRFLVSODWLQWUHDWPHQWPLJKWVWLOOEHQHÀWIURP:HHLQKLELWLRQe. Addi WLRQDOFHOOF\FOHGLVWULEXWLRQVRI+16&&DQGRYDULDQFDQFHUFHOOOLQHVDUHVKRZQLQRUGHURI(&YDOXH )LJXUHJ&HOOF\FOHZDVDOWHUHGLQDOOWHVWHGFHOOOLQHVPRVWVKRZLQJDQLQFUHDVHGQRQUHSOLFDWLQJ 6RU*SKDVH

Figure S4: Cell cycle deregulation was found upon Adavosertib treatment. a-c.+16&&FHOOOLQHV 806&&%a986&&2(bDQG806&&cDOOVKRZHGGHFUHDVHGS&'.<DQGLQ FUHDVHG'1$GDPDJHո+$[6HUXSRQ:HHLQKLELWLRQd. ([DPSOHVKRZQRI+16&&FHOOOLQH 806&&$IRUWKHSROHWRSROHPHDVXUHPHQWVLQXQWUHDWHGDQG$GDYRVHUWLEWUHDWHGFRQGLWLRQV REWDLQHGZLWK/HLFD/$6;VRIWZDUH

a

e

c

a

b

d

)LJXUH6&RPELQDWLRQWKHUDS\RI$GDYRVHUWLEZLWK3$53LQKLELWRU7DOD]RSDULEճLUUDGLDWLRQ and Chk1 inhibitor Rabusertib. a.$GDYRVHUWLEZDVFRPELQHGZLWK3$53LQKLELWRU7DOD]RSDULEIRU K 1R LQFUHDVHG VHQVLWLYLW\ ZDV REVHUYHG DIWHU FRPELQLQJ WKHVH WUHDWPHQWV LQ +16&& FHOO OLQHV 806&&$DQG986&&b.&RPELQDWLRQRIոLUUDGLDWLRQZLWK$GDYRVHUWLEVOLJKWO\VHQVLWL]HG +16&&FHOOOLQHV986&&DQG)D'XWR:HHLQKLELWLRQc.&KNDQG:HHDUHERWKLPSRUWDQW

 

4

Gene CCH- FA HN-SCC-2 VU- SCC- 1131 VU- SCC- 1365 VU- SCC- 1604 VU-SCC -120 (refer ence ) VU- SCC- OE UM- SCC- 11B UM- SCC- 22B UM- SCC- 104 UM- SCC- 47 UT -SCC- 45 VU- SCC- 147 Fibro- blasts #50 Fibro- blasts #54 Fibro- blasts VU-1678

CCDC99                  CCT4                  CCT7                 CCT8                 CD207                  CDC40                  CDC5L                 CDCA8                 CDK1                 CDK1 1A                  CELF5                 CENPE                 CEP72                 CHMP2A                 CKAP5                 COL10A1                 COL20A1                 COP A                 COPB1                 COPB2                 COPG1      na          COPZ1                 COPZ2                 CRNKL1                 CSDC2                CSNK2A2                 CST A   na             CWC15                 T

able S1: Median of triplicate viability scores of siRNAs per cell line

#. Gene CCH- FA HN-SCC-2 VU- SCC- 1131 VU- SCC- 1365 VU- SCC- 1604 VU-SCC -120 (refer ence ) VU- SCC- OE UM- SCC- 11B UM- SCC- 22B UM- SCC- 104 UM- SCC- 47 UT -SCC- 45 VU- SCC- 147 Fibro- blasts #50 Fibro- blasts #54 Fibro- blasts VU-1678

ADAMTS17 *                 AGFG2                  AHSP ƾ                 ALDH18A1                 ANAPC1                 ANAPC4                 AP5S1   na             APCDD1L Ȼ                  AQR                 ARCN1                 ARFGEF1                  ARHGAP20                 ARL14                ARSG                 ASB16                 ASNS         na        A T P6AP1                  BIRC5                 C14orf129                 C19orf59                 C22orf29                  C8orf31                 CACTIN                 CALCOCO2                 CCBL2                 CCDC153                 T able S1 (continued)